0000711404-23-000072 | 10-K | XBRL Viewer

Print Document View Excel Document

Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Deferred tax assets:
Accounts receivable	$ 7.5	$ 4.9
Inventories	14.3	6.3
Accrued liabilities, reserves and compensation accruals	94.8	79.9
Foreign deferred tax assets	2,369.5	2,500.5
Share-based compensation	14.8	14.5
Net operating loss and tax credit carryforwards	24.3	19.6
Capitalized research and experimental expenses	23.6	15.4
Total gross deferred tax assets	2,548.8	2,641.1
Less: valuation allowance	(20.7)	(60.1)
Deferred tax assets	2,528.1	2,581.0
Deferred tax liabilities:
Tax deductible goodwill	(47.4)	(39.7)
Intangible assets	(132.4)	(153.8)
Plant and equipment	(51.2)	(48.8)
Foreign deferred tax liabilities	(49.0)	(45.5)
Total gross deferred tax liabilities	(280.0)	(287.8)
Net deferred tax assets	$ 2,248.1	$ 2,293.2

Business Segment Information

12 Months Ended

Oct. 31, 2023

Segment Reporting [Abstract]

Business Segment Information

Note 12. Business Segment Information

The Company discloses information about its operating segments, which were established based on the way that management organizes segments within the Company for making operating decisions and assessing financial performance. The Company's two operating segments are described below.

•CooperVision. Competes in the worldwide contact lens market by developing, manufacturing and marketing a broad range of products for contact lens wearers, featuring advanced materials and optics.

•CooperSurgical. Competes in the general health care market with a focus on advancing the health of women, babies and families through a diversified portfolio of products and services focusing on women's health and fertility.

The Company uses operating income, as presented in our financial reports, as the primary measure of segment profitability. The Company does not allocate costs from corporate functions to segment operating income. The Company uses the same accounting policies to generate segment results as it does for consolidated results.

No customers accounted for 10% or more of our consolidated net revenue in fiscal 2023, 2022 and 2021.

Total identifiable assets are those used in continuing operations except cash and cash equivalents, which the Company includes as corporate assets.

The following table presents a summary of our business segment net sales:


(In millions)	2023		2022		2021
CooperVision net sales by category:
Toric lens	$	828.7	$	737.4	$	697.5
Multifocal lens	305.7		264.4		238.6
Single-use sphere lens	705.4		661.6		616.3
Non single-use sphere, other	583.9		579.9		599.6
Total CooperVision net sales	2,423.7		2,243.3		2,152.0
CooperSurgical net sales by category:
Office and surgical	689.5		633.6		451.3
Fertility	480.0		431.5		319.2
Total CooperSurgical net sales	1,169.5		1,065.1		770.5
Total net sales	$	3,593.2	$	3,308.4	$	2,922.5

Information by business segment for each of the years in the three-year period ended October 31, 2023 follows:


(In millions)	CooperVision		CooperSurgical		Corporate		Consolidated
2023
Net sales	$	2,423.7	$	1,169.5	$	—	$	3,593.2
Operating income (loss)	$	587.7	$	16.1	$	(70.7)	$	533.1
Interest expense							105.3
Other expense, net							14.9
Income before income taxes							$	412.9
Identifiable assets	$	7,044.0	$	4,351.8	$	263.1	$	11,658.9
Depreciation expense	$	156.9	$	24.6	$	—	$	181.5
Amortization expense	$	32.9	$	153.3	$	—	$	186.2
Capital expenditures	$	364.4	$	28.1	$	—	$	392.5
2022
Net sales	$	2,243.3	$	1,065.1	$	—	$	3,308.4
Operating income (loss)	$	494.3	$	67.1	$	(53.8)	$	507.6
Interest expense							57.3
Other (income), net							(25.0)
Income before income taxes							$	475.3
Identifiable assets	$	6,778.9	$	4,407.8	$	305.6	$	11,492.3
Depreciation expense	$	144.5	$	22.1	$	—	$	166.6
Amortization expense	$	32.3	$	147.2	$	—	$	179.5
Capital expenditures	$	223.0	$	19.0	$	—	$	242.0
2021
Net sales	$	2,152.0	$	770.5	$	—	$	2,922.5
Operating income (loss)	$	481.3	$	71.8	$	(47.3)	$	505.8
Interest expense							23.1
Other expense, net							(8.8)
Income before income taxes							$	491.5
Identifiable assets	$	6,965.9	$	2,395.6	$	244.7	$	9,606.2
Depreciation expense	$	148.3	$	14.9	$	—	$	163.2
Amortization expense	$	35.7	$	110.4	$	—	$	146.1
Capital expenditures	$	190.0	$	24.4	$	—	$	214.4

Information by geographical area by country of domicile for each of the years in the three-year period ended October 31, 2023 follows:


(In millions)	United States		Europe		Rest of World, Other Eliminations & Corporate		Consolidated
2023
Net sales to unaffiliated customers	$	1,812.2	$	1,041.2	$	739.8	$	3,593.2
Sales between geographic areas	563.1		1,016.7		(1,579.8)		—
Net sales	$	2,375.3	$	2,057.9	$	(840.0)	$	3,593.2
Operating income	$	—	$	516.2	$	16.9	$	533.1
Long-lived assets	$	1,027.6	$	325.9	$	279.1	$	1,632.6
2022
Net sales to unaffiliated customers	$	1,638.5	$	987.2	$	682.7	$	3,308.4
Sales between geographic areas	514.4		897.3		(1,411.7)		—
Net sales	$	2,152.9	$	1,884.5	$	(729.0)	$	3,308.4
Operating (loss) income	$	71.8	$	403.8	$	32.0	$	507.6
Long-lived assets	$	856.1	$	310.8	$	266.0	$	1,432.9
2021
Net sales to unaffiliated customers	$	1,339.2	$	957.9	$	625.4	$	2,922.5
Sales between geographic areas	494.9		815.1		(1,310.0)		—
Net sales	$	1,834.1	$	1,773.0	$	(684.6)	$	2,922.5
Operating (loss) income	$	(26.8)	$	416.2	$	116.4	$	505.8
Long-lived assets	$	737.5	$	377.2	$	232.9	$	1,347.6

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

Financial Derivatives and Hedging - Derivative Instruments Recognized in Condensed Consolidated Statements of Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Interest expense \| Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Loss recognized on derivatives within interest expense	$ (43.1)	$ (2.3)	$ 8.0

Income Taxes - Income Before Income Taxes (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Income before income taxes:
United States	$ (135.7)	$ 31.4	$ (31.0)
Foreign	548.6	443.9	522.5
Income before income taxes	$ 412.9	$ 475.3	$ 491.5

- Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(11))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479557/942-235-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-SubTopic 20
-Topic 940
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481913/940-20-25-1

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Business Segment Information - Business Segment Net Sales (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Segment Reporting Information [Line Items]
Net sales	$ 3,593.2	$ 3,308.4	$ 2,922.5
CooperVision
Segment Reporting Information [Line Items]
Net sales	2,423.7	2,243.3	2,152.0
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	1,169.5	1,065.1	770.5
Toric lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	828.7	737.4	697.5
Multifocal lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	305.7	264.4	238.6
Single-use sphere lens \| CooperVision
Segment Reporting Information [Line Items]
Net sales	705.4	661.6	616.3
Non single-use sphere, other \| CooperVision
Segment Reporting Information [Line Items]
Net sales	583.9	579.9	599.6
Office and surgical \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	689.5	633.6	451.3
Fertility \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	$ 480.0	$ 431.5	$ 319.2

Stockholders' Equity - Changes in Accumulated Other Comprehensive Income (Loss) Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	$ 7,174.7	$ 6,942.0	$ 3,824.8
Gross change in value	11.6	(90.7)	146.3
Tax effect	1.4	(34.8)	(15.6)
Ending balance	7,551.0	7,174.7	6,942.0
Total
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(466.8)	(341.3)	(472.0)
Ending balance	(453.8)	(466.8)	(341.3)
Foreign Currency Translation Adjustment
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(555.0)	(320.3)	(402.3)
Gross change in value	17.0	(234.7)	82.2
Tax effect	0.0	0.0	(0.2)
Ending balance	(538.0)	(555.0)	(320.3)
Derivatives
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	94.4	13.1	(13.0)
Gross change in value	(9.4)	107.4	34.3
Tax effect	2.4	(26.1)	(8.2)
Ending balance	87.4	94.4	13.1
Minimum Pension Liability
AOCI Attributable to Parent, Net of Tax [Roll Forward]
Beginning balance	(6.2)	(34.1)	(56.7)
Gross change in value	4.0	36.6	29.8
Tax effect	(1.0)	(8.7)	(7.2)
Ending balance	$ (3.2)	$ (6.2)	$ (34.1)

- Definition

Amount before tax, after reclassification adjustments of other comprehensive income (loss).

+ References + Details

- Definition

Amount of tax expense (benefit) allocated to other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 12
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-12

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-4

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-10

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482659/740-20-45-11

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 20
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482659/740-20-45-2

+ Details

- Definition

Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483421/250-10-45-24

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 23
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483421/250-10-45-23

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483421/250-10-45-5

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (h)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (i)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-5

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 29: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-11

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 205
-Name Accounting Standards Codification
-Section 45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480767/946-205-45-3

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-3

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 38: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 39: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 40: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 41: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-15

Reference 42: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 45
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481231/810-10-45-16

Reference 43: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4I
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481175/810-10-55-4I

+ Details

Intangible Assets

12 Months Ended

Oct. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Intangible Assets

Note 4. Intangible Assets

Goodwill

The Company has three reporting units: CooperVision and within the CooperSurgical segment, Office/Surgical and Fertility, reflecting the current way the Company manages its business. There was no impairment of goodwill in its reporting units in fiscal 2023, 2022, and 2021.


(In millions)	CooperVision		CooperSurgical		Total




Balance at October 31, 2022	$	1,710.3	$	1,899.4	$	3,609.7
Net changes	7.7		(3.6)		4.1

Foreign currency translation adjustment	29.6		(18.9)		10.7
Balance at October 31, 2023	$	1,747.6	$	1,876.9	$	3,624.5

Of the October 31, 2023, goodwill balance, $237.6 million for CooperSurgical and $20.1 million for CooperVision is expected to be deductible for tax purposes. Of the October 31, 2022, goodwill balance, $214.1 million for CooperSurgical and $22.4 million for CooperVision was expected to be deductible for tax purposes.

Other Intangible Assets


	October 31, 2023				October 31, 2022
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted-average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	208.9	$	81.1	$	209.6	$	62.4	15
Composite intangible asset	1,061.9		424.8		1,061.9		354.0		15
Technology	494.5		335.4		504.1		317.5		13
Customer relationships	1,099.2		345.8		1,092.7		287.0		19
License and distribution rights and other	51.6		28.0		50.7		23.8		11
	2,916.1		$	1,215.1	2,919.0		$	1,044.7	16
Less: accumulated amortization and translation	1,215.1				1,044.7
Intangible assets with definite lives, net	$	1,701.0			$	1,874.3
Intangible assets with indefinite lives, net (1)	9.3				10.8
Total other intangibles, net	$	1,710.3			$	1,885.1

(1) Intangible assets with indefinite lives include technology and trademarks.

Balances include foreign currency translation adjustments.

As of October 31, 2023, the estimate of future amortization expenses for intangible assets with definite lives is as follows:


Fiscal years:	(In millions)
2024	$	179.5
2025	169.5
2026	162.0
2027	147.7
2028	143.2
Thereafter	899.1
Total remaining amortization for intangible assets with definite lives	$	1,701.0

In the fourth quarter of fiscal 2023, CooperVision fully impaired some intangible assets associated with the discontinuation of certain products. The carrying value of these intangible assets were immaterial. The Company performed its annual impairment assessment in the third quarter of fiscal 2023 and determined there was no other impairment to either its definite-lived or indefinite-lived intangible assets during fiscal 2023.

There were no impairment to the Company's definite-lived or indefinite-lived intangible assets during fiscal 2022 and 2021.

Organization and Significant Accounting Policies - Narrative (Details) $ in Millions	12 Months Ended
	Oct. 31, 2023 business_unit	Oct. 31, 2022 USD ($)
Property, Plant and Equipment [Line Items]
Number of business units \| business_unit	2
Exit charges		$ 33.2
Cost of sales
Property, Plant and Equipment [Line Items]
Exit charges		26.7
Selling, general and administrative expense
Property, Plant and Equipment [Line Items]
Exit charges		$ 6.5
Minimum
Property, Plant and Equipment [Line Items]
Capitalized contract cost, amortization period (or less)	1 year
Property, plant and equipment, useful life	3 years
Minimum \| Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	30 years
Maximum
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	15 years
Maximum \| Building
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life	40 years

Earnings Per Share - Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Earnings Per Share [Abstract]
Net income	$ 294.2	$ 385.8	$ 2,944.7
Basic:
Weighted-average common shares (in shares)	49.5	49.3	49.2
Basic earnings per share (in dollars per share)	$ 5.94	$ 7.83	$ 59.80
Diluted:
Effect of dilutive stock options (in shares)	0.3	0.4	0.6
Diluted weighted average common shares (in shares)	49.8	49.7	49.8
Diluted earnings per share (in dollars per share)	$ 5.91	$ 7.76	$ 59.16

- Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-10

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(25))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(27))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 52
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482635/260-10-55-52

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-7

+ Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

Stock Plans - Stock Option Plans (Details)	12 Months Ended
Stock Plans - Stock Option Plans (Details)	Oct. 31, 2023 USD ($) $ / shares shares
Number of Shares
Vested and expected to vest at end of period (in shares) \| shares	1,059,841
Vested and exercisable at end of period (in shares) \| shares	729,591
Weighted- Average Exercise Price Per Share
Vested and expected to vest at end of period (in dollars per share) \| $ / shares	$ 276.11
Vested and exercisable at end of period (in dollars per share) \| $ / shares	$ 248.34
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Vested and expected to vest at end of period, Weighted-Average Remaining Contractual Term (in years)	5 years 3 months 25 days
Vested and exercisable at end of period, Weighted-Average Remaining Contractual Term (in years)	4 years 4 months 17 days
Vested and expected to vest at end of period, Aggregate Intrinsic Value \| $	$ 53,475,275
Vested and exercisable at end of period, Aggregate Intrinsic Value \| $	$ 50,797,891
Stock Options
Number of Shares
Outstanding, beginning balance (in shares) \| shares	1,063,843
Granted (in shares) \| shares	86,241
Exercised (in shares) \| shares	(71,808)
Forfeited or expired (in shares) \| shares	(720)
Outstanding, ending balance (in shares) \| shares	1,077,556
Weighted- Average Exercise Price Per Share
Outstanding, beginning balance (in dollars per share) \| $ / shares	$ 264.85
Granted (in dollars per share) \| $ / shares	329.83
Exercised (in dollars per share) \| $ / shares	155.45
Forfeited or expired (in dollars per share) \| $ / shares	337.72
Outstanding, ending balance (in dollars per share) \| $ / shares	$ 277.29
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Outstanding, ending balance, Weighted Average Remaining Contractual Term (in years)	5 years 4 months 9 days
Outstanding, ending balance, Aggregate Intrinsic Value \| $	$ 53,510,367

Acquisitions and Joint Venture	12 Months Ended
Acquisitions and Joint Venture	Oct. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Acquisitions and Joint Venture	Note 3. Acquisitions and Joint Venture All acquisitions were funded by cash generated from operations or facility borrowings. The Company believes these acquisitions strengthen CooperSurgical's and CooperVision's businesses through the addition of new distributors or complementary products and services. Fiscal Year 2023 On November 1, 2022, CooperVision completed the acquisition of a privately-held U.S.-based company that provides a broad portfolio of technologically advanced contact lens products, including scleral and hybrid lenses. The purchase price of the acquisition was $33.0 million. Assets acquired primarily comprised of $12.6 million of customer relationship related intangibles, $7.6 million of technology, $5.1 million of net assets and $7.7 million of goodwill. The goodwill is not deductible for tax purposes. Fiscal Year 2022 On May 31, 2022, CooperVision completed the acquisition of a privately-held Denmark-based contact lens distributor focusing on orthokeratology and scleral contact lenses. This acquisition expands CooperVision's ortho-k eye care portfolio in the Nordic market. On April 6, 2022, CooperSurgical completed the acquisition of a private cryopreservation services company that specializes in cryogenic services. Refer to the "Joint Venture" section below for details on formation of a joint venture with Essilor International and related activities that occurred in fiscal year 2023 and 2022 following the acquisition of SightGlass Vision, Inc. (SGV) in fiscal year 2021. On April 6, 2022, CooperSurgical entered into an asset purchase agreement to acquire Cook Medical's Reproductive Health business, a manufacturer of minimally invasive medical devices focused on the fertility, obstetrics and gynecology markets. The aggregate consideration is $875.0 million in cash, with $675.0 million payable at the closing and the remaining $200.0 million payable in $50.0 million installments following each of the first, second, third and fourth anniversaries of the closing. The transaction is subject to customary closing conditions, such as receipt of required regulatory approvals. During the year ended October 31, 2023, CooperSurgical determined that the fulfillment of certain closing conditions related to regulatory approvals was no longer probable and paid $45.0 million in expenses for a termination fee under the asset purchase agreement on August 9, 2023. The termination fee is recorded in "Selling, general and administrative expense" on the Consolidated Statements of Income. Refer to the "Subsequent Event" section below for details on the revised scope of the transaction and the closing of the updated transaction. On December 17, 2021, CooperSurgical completed the acquisition of 100% of the equity interests in Generate Life Sciences (Generate), a privately held leading provider of donor egg and sperm for fertility treatments, fertility cryopreservation services and newborn stem cell storage (cord blood & cord tissue), and paid an aggregate purchase consideration of approximately $1.663 billion, reflecting working capital, and other adjustments. The cash consideration was funded through a combination of $1.5 billion in proceeds from the issuance of a senior unsecured term loan and available cash on hand. Joint Venture On January 19, 2021, CooperVision acquired all of the remaining equity interests of SGV, a privately-held medical device company that developed spectacle lenses for myopia management. The transaction included potential payments of future consideration that were contingent upon the achievement of the regulatory approval milestone (the regulatory approval payment) and the acquired business reaching certain revenue thresholds over a specified period (the revenue payments). The undiscounted range of the contingent consideration was zero to $139.1 million payable to the other former equity interest owners. The fair value of the regulatory approval payment was determined using an option pricing framework based on the expected payment under the contractual terms and the estimates of the probability of achieving the regulatory approval. The fair value of the revenue payments was determined using a Monte Carlo simulation based on the revenue projections and the expected payment for each simulation. In March 2022, the entities amended the terms of the contingent consideration, which resulted in CooperVision paying $42.9 million to the former equity interest owners in exchange for the elimination of the revenue payments to such former equity interest owners. CooperVision recognized a net gain of $12.2 million during fiscal 2022. Further, CooperVision and Essilor International SAS (Essilor) executed a Contribution Agreement and a Stock Purchase Agreement (the "Agreements") in March 2022. Essilor paid CooperVision $52.1 million in exchange for a 50% interest in SGV and their proportionate share of the revenue payments. As part of the Agreements, each party contributed their interest in SGV and $10 million in cash to form a new joint venture. CooperVision then remeasured the fair value of its retained equity investment in the joint venture at $90.0 million which resulted in a $56.9 million gain in Other (income) expense on deconsolidation of SGV in fiscal 2022. During fiscal 2023, CooperVision determined that approval would not be achieved within the timeline set forth in the contractual terms of the regulatory approval payment and released the remaining $31.8 million contingent consideration liability. Subsequent Event On November 1, 2023, CooperSurgical closed the acquisition of select assets of Cook Medical for an aggregate consideration of $300.0 million, with $200.0 million paid at closing and $100.0 million to be paid in two $50.0 million annual installments. The assets acquired primarily comprised of minimally invasive medical devices within the obstetrics, doppler monitoring and gynecology surgery markets. The Company is in the process of finalizing purchase accounting information.

Stockholders' Equity - Narrative (Details) $ / shares in Units, $ in Millions		6 Months Ended				12 Months Ended
	Dec. 07, 2023	Oct. 31, 2023 USD ($) $ / shares	Apr. 30, 2023 $ / shares	Oct. 31, 2022 $ / shares	Apr. 30, 2022 $ / shares	Oct. 31, 2023 USD ($) $ / shares shares	Oct. 31, 2022 USD ($) $ / shares shares	Oct. 31, 2021 USD ($) $ / shares	Mar. 31, 2017 USD ($)	Dec. 31, 2011 USD ($)
Class of Stock [Line Items]
Share repurchase program, maximum amount authorized									$ 1,000.0	$ 500.0
Share repurchase program, remaining authorized amount		$ 256.4				$ 256.4
Stock repurchase (in shares) \| shares						0	191,200
Treasury stock repurchase							$ 78.5	$ 24.8
Average repurchase price per share (in dollars per share) \| $ / shares							$ 410.41
Dividends declared on common stock (in dollars per share) \| $ / shares						$ 0.06	0.06
Dividends on common stock (in dollars per share) \| $ / shares		$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03
Dividends on common stock						$ 3.0	$ 3.0	$ 3.0
Subsequent Event
Class of Stock [Line Items]
Stock split, conversion ratio	4

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Statement of Financial Position [Abstract]
Trade accounts receivable, allowance for credit losses	$ 31.3	$ 20.7
Preferred stock, par value (in dollars per share)	$ 0.10	$ 0.10
Preferred stock, authorized (in shares)	1,000,000.0	1,000,000.0
Preferred stock, issued (in shares)	0	0
Preferred stock, outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common stock, authorized (in shares)	120,000,000.0	120,000,000.0
Common stock, issued (in shares)	53,900,000	53,800,000
Common stock, outstanding (in shares)	49,500,000	49,300,000
Treasury stock (in shares)	4,400,000	4,500,000

Earnings Per Share

12 Months Ended

Oct. 31, 2023

Earnings Per Share [Abstract]

Earnings Per Share

Note 7. Earnings Per Share


Years Ended October 31,
(In millions, except for earnings per share)	2023		2022		2021
Net income	$	294.2	$	385.8	$	2,944.7
Basic:
Weighted-average common shares	49.5		49.3		49.2
Basic earnings per share	$	5.94	$	7.83	$	59.80
Diluted:
Weighted-average common shares	49.5		49.3		49.2
Effect of dilutive stock plans	0.3		0.4		0.6
Diluted weighted-average common shares	49.8		49.7		49.8
Diluted earnings per share	$	5.91	$	7.76	$	59.16

The following table sets forth stock options to purchase our common stock and restricted stock units that were not included in the diluted earnings per share calculation because their effect would have been antidilutive for the periods presented:


Years Ended October 31,
(In thousands, except exercise prices)	2023	2022	2021
Stock option shares excluded	311	227	107
Exercise prices	$300.12 - $406.17	$300.12 - $406.17	$	345.74
Restricted stock units excluded	15	87	2

Stockholders' Equity (Tables)

12 Months Ended

Oct. 31, 2023

Stockholders' Equity Note [Abstract]

Changes in accumulated other comprehensive (loss) income

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	82.2		34.3		29.8		146.3
Tax effect	(0.2)		(8.2)		(7.2)		(15.6)

Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)
Gross change in value	$	(234.7)	$	107.4	$	36.6	$	(90.7)
Tax effect	—		(26.1)		(8.7)		(34.8)

Balance at October 31, 2022	$	(555.0)	$	94.4	$	(6.2)	$	(466.8)
Gross change in value	$	17.0	$	(9.4)	$	4.0	$	11.6

Tax effect	—		2.4		(1.0)		1.4
Balance at October 31, 2023	$	(538.0)	$	87.4	$	(3.2)	$	(453.8)

The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:


(In millions)	Amount
Balance gain as of October 31, 2021	$	17.2
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($79.7, net of tax)	105.1
Amount reclassified from other comprehensive income into earnings, gross ($1.7, net of tax)	2.2
Balance gain as of October 31, 2022	$	124.5
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($25.7, net of tax)	33.7
Amount reclassified from other comprehensive income into earnings, gross ($(32.7), net of tax)	(43.1)
Balance gain as of October 31, 2023	$	115.1

Organization and Significant Accounting Policies

12 Months Ended

Oct. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization and Significant Accounting Policies

Note 1. Organization and Significant Accounting Policies

Organization

The Cooper Companies, Inc. (Cooper, we or the Company) is a global medical device company publicly traded on the Nasdaq (Nasdaq: COO). Prior to September 26, 2023, Cooper's common stock traded on the New York Stock Exchange under the symbol "COO". Cooper operates through two business units, CooperVision and CooperSurgical.

•CooperVision primarily develops, manufactures and markets a broad range of soft contact lenses for the worldwide vision correction market.

•CooperSurgical primarily develops, manufactures, markets medical devices and procedures solutions, and provides services to improve health care delivery to women, babies and families.

Principles of Consolidation

The financial statements in this report include the results of all of Cooper's consolidated entities. All significant intercompany transactions and balances are eliminated on consolidation.

Use of Estimates

The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results.

Revenue Recognition

Net Sales

The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers may subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations.

Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note 12. Business Segment Information for disaggregation of revenue.

Reserves for Variable Consideration

Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently.

Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known

market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract.

Trade Discounts and Allowances

The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.

Product Returns

Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Historically, returns have been infrequent and insignificant relative to our total sales. Our refund liability for product returns is included in "Other current liabilities" in our Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers.

Rebates and Chargebacks

Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served.

Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical portfolio in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis.

Contract Liabilities

Deferred revenue primarily represents prepaid stem cell storage as part of the CooperSurgical business unit. Revenue related to stem cell storage is recognized over the service period, which can range from one year to the lifetime of a customer. The current portion of the deferred revenue balances at the beginning of each year presented were generally fully recognized in the subsequent 12-month period.

Share-Based Compensation

We grant various share-based compensation awards, including stock options, performance unit shares, restricted stock and restricted stock units. The Company accounts for share-based compensation expense based on estimated grant-date fair value, and expenses the amount over the vesting period of the award. Determining the fair value of share-based awards at the grant date requires judgment, including estimating Cooper's stock price volatility, employee exercise behaviors and related employee forfeiture rates.

The expected life of the share-based awards is based on the expected time to post-vesting forfeiture and/or exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. In determining the expected volatility, management considers implied volatility from publicly-traded options on Cooper's common stock at the date of grant, historical volatility and other factors. The risk-free interest rate is based on the continuous rates provided by the United States Treasury with a term equal to the expected life of the award. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant.

Forfeitures are estimated at the time of grant, based on historical experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.

Foreign Currency Translation

Most of our operations outside the United States use their local currency as their functional currency. We translate these assets and liabilities into U.S. dollars at year-end exchange rates. We translate income and expense accounts at average exchange rates for the period. We record gains and losses from the translation of financial statements in foreign currencies into U.S. dollars in other comprehensive income. We record gains and losses from changes in exchange rates on transactions denominated in currencies other than each reporting location's functional currency in net income for each period.

Financial Derivatives and Hedging

Derivatives are recorded on the Consolidated Balance Sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting.

The gain or loss on derivative instruments designated and qualifying for cash flow hedge accounting is deferred in other comprehensive income. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. Deferred gains or losses from designated cash flow hedges are reclassified into earnings in the period that the hedged interest expense affects earnings. The effectiveness of cash flow hedges is assessed at inception and quarterly thereafter. The Company does not offset fair value amounts recognized for derivative instruments in its Consolidated Balance Sheets for presentation purposes.

Fair Value Measurements

The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.

Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.

Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

The carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms.

The carrying value of the Company's revolving credit facility and term loans approximates fair value based on current market rates (Level 2). Refer to Note 5. Financing Arrangements for further information.

The fair value of the Company's interest rate swap contracts is measured on a recurring basis by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates (forward curves) derived from observable market interest rate curves. The interest rate swap contracts were categorized as Level 2 in the fair value hierarchy, as the inputs to the derivative pricing model are generally observable and do not contain a high level of subjectivity. The fair value of derivative instruments is included in "Other assets" in our Consolidated Balance Sheets. On our Consolidated Financial Statements. the gain or loss on the derivatives is recorded as a component of "Accumulated other comprehensive loss" and subsequently reclassified into "Interest expense" in the same period during which the hedged transaction affects earnings. Refer to Note 13. Financial Derivatives and Hedging for further information.

The Company uses fair value measures for assets and liabilities acquired in an acquisition, which are considered a Level 3 measurement. Contingent consideration for which a liability is recorded and the initial measurement of the joint venture interest are also categorized as Level 3 in the fair value hierarchy; and the change in fair value is recognized in "Selling, general and administrative expense" in the Consolidated Statements of Income. The fair value is measured by discounting expected future cash flows. The discount rate used for cash flows reflects capital market conditions and the specific risks associated with the business. Refer to Note 3. Acquisitions and Joint Venture for further information.

Income Taxes

Income taxes are estimated based on enacted income tax laws and the results of operations in each jurisdiction. Deferred tax assets and liabilities are estimated based on temporary differences between the financial reporting basis and income tax basis of assets and liabilities. Deferred tax assets are also estimated based on net operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance to the extent it is more likely than not they are not expected to be realized. Adjustments to deferred tax assets and liabilities due to changes in tax laws, changes in jurisdiction from intra-group transfers of assets, and changes in judgment regarding a valuation allowance are recognized in provision for income taxes in the quarter in which such changes occur. Long-term tax payable is estimated income tax to be paid for unrecognized tax benefits. A tax benefit is recognized if it is more likely than not a tax position will be sustained based on its technical merits in a tax authority examination, based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. Adjustments to unrecognized tax benefits due to changes in judgment are recognized in provision for income taxes in the quarter in which such changes occur. Interest and penalties related to unrecognized tax benefits are recognized in provision for income taxes.

Earnings Per Share

We determine basic earnings per share (EPS) by using the weighted-average number of shares outstanding. We determine diluted EPS by increasing the weighted-average number of shares outstanding in the denominator by the number of outstanding dilutive equity awards using the treasury stock method.

Cash and Cash Equivalents

The Company considers all short-term, highly liquid investments purchased with maturities of three months or less to be cash equivalents.

Inventories

Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis.


October 31, (In millions)	2023		2022
Raw materials	$	207.3	$	173.7
Work-in-process	19.0		15.2
Finished goods	509.3		439.8
	$	735.6	$	628.7

In assessing the value of inventories, we make estimates and judgments regarding aging of inventories and other relevant issues potentially affecting the salable condition of products and estimated prices at which those products will sell. On an ongoing basis, we review the carrying value of our inventory, measuring number of months on hand and other indications of salability. We reduce the value of inventory if there are indications that the carrying value is greater than net realizable value, resulting in a new, lower-cost basis for that inventory. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. While estimates are involved, historically, obsolescence has not been a significant factor due to long product dating and lengthy product life cycles.

Property, Plant and Equipment

We record property, plant, and equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally 3 to 15 years except for buildings which are depreciated over 30 to 40 years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.


October 31, (In millions)	2023		2022
Land and improvements	$	20.2	$	18.7
Buildings and improvements	488.5		415.6
Machinery and equipment	2,187.1		1,973.6
Construction in progress	486.3		393.0
Property, plant and equipment, at cost	$	3,182.1	$	2,800.9
Less: Accumulated depreciation	1,553.3		1,387.2
Property, plant and equipment, net	$	1,628.8	$	1,413.7
Finance lease ROU assets, net	3.8		19.2
	$	1,632.6	$	1,432.9

Leases

We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. The Company primarily has operating leases for office, manufacturing and warehouse space, vehicles, and office equipment.

Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future lease payments over the lease term. The lease term reflects the noncancellable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the Consolidated Balance Sheets. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis.

The Company’s operating leases typically include non-lease components such as common-area maintenance costs. The Company has elected to include non-lease components with lease payments for the purpose of calculating lease right-of-use assets and liabilities, to the extent that they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments.

Leases with a term of one year or less are not recognized in the Consolidated Balance Sheets, while the associated lease payments are expensed in the Consolidated Statements of Income and Comprehensive Income on a straight-line basis over the lease term.

Operating leases are classified in “Other current liabilities”, “Other liabilities”, and “Other assets” in our Consolidated Balance Sheets. Operating lease expense is recognized on a straight-line basis over the expected lease term and included in "Selling, general and administrative expense" in our Consolidated Statements of Income. Financing leases are classified in "Property, plant and equipment, net", "Short-term debt", and "Long-term debt" in our Consolidated Balance Sheets. See Note 2. Operating Leases and Note 5. Financing Arrangements for further information.

Cloud Computing Arrangements

The Company capitalizes certain costs related to the acquisition and development of internal use software, including implementation costs incurred in a cloud computing arrangement, during the application development stages of projects. Capitalized implementation costs are amortized on a straight-line basis over the expected term of the hosting arrangement, which includes consideration of the non-cancellable contractual term and reasonably certain renewals. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred. Implementation costs are included in “Other assets” in our Consolidated Balance Sheets. Amortization of capitalized implementation costs is included in the same line item in the Consolidated Statements of Income as the expense for fees for the associated hosting arrangement.

Valuation of Goodwill

We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. Goodwill is tested for impairment at the reporting unit level by performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. We perform a qualitative assessment to test each reporting unit's goodwill for impairment, which includes industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit.

Long-lived Assets

We review long-lived assets held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset group are compared to the asset group's carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value.

Indefinite-lived Intangible Assets

We assess indefinite-lived intangible assets annually in the third quarter of the fiscal year, or whenever events or changes in circumstances indicate that the carrying amount of an indefinite-lived intangible asset (asset group) may not be recoverable. We evaluate whether the indefinite-lived intangible asset is impaired by comparing its carrying value to its fair value. If the carrying value of an indefinite-lived intangible asset is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value.

Business Combinations

We routinely consummate business combinations. Results of operations for acquired companies are included in our consolidated results of operations from the date of acquisition. We recognize separately from goodwill, the identifiable assets acquired, including acquired in-process research and development, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date fair values as defined by accounting standards related to fair value measurements. Key assumptions routinely utilized in allocation of purchase price to intangible assets include discount rates and projected financial information such as revenue projections for companies acquired. As of the acquisition date, goodwill is measured as the excess of consideration given, over the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed. Direct acquisition costs are expensed as incurred.

For business acquisitions, the Company records tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition.

Litigation

We are subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. If we believe the likelihood of an adverse legal outcome is probable and the amount is estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company.

Treasury Stock

We record treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.

Exit Charges

During the second quarter of fiscal 2022, the Company initiated a plan to exit its contact lens care business, a non-core business unit of the CooperVision segment, which was completed in fiscal 2023. Exit charges recognized during the year ended October 31, 2023, were not material. Exit charges recognized during the year ended October 31, 2022, were $33.2 million, of which $26.7 million were recognized in "Cost of sales" and $6.5 million were recognized in "Selling, general and administrative expense" in our Consolidated Statements of Income. Exit charges primarily related to inventory write-down, asset impairments and employee-related costs.

Government Assistance

The Company at times receives government assistance primarily to support manufacturing capital expansion, to create or retain jobs, or to provide tax credits mainly for eligible research and development activities. The Company generally accounts for such government assistance by analogy to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance and recognizes the assistance when it is probable that it will be received by complying with the prerequisite terms and conditions. The government assistance is recognized in income as a reduction to the cost basis of the applicable property, plant, and equipment or reduction to the related expense.

Accounting Pronouncements Recently Adopted

In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard was effective for fiscal years beginning after December 15, 2021. The Company adopted this guidance prospectively on November 1, 2022, and such adoption did not have a material impact on the Company's Consolidated Financial Statements.

In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. ASU 2022-06 defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2024. Effective February 1, 2023, the Company transitioned its credit agreements from LIBOR to the Secured Overnight Financing Rate ("SOFR"). The Company adopted this guidance prospectively on February 1, 2023, and it did not have a material impact on the Consolidated Financial Statements.

Accounting Pronouncements Issued Not Yet Adopted

No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Financial Statements.

Stock Plans - Compensation Expense and Related Income Tax Benefit for Share-Based Awards (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 62.1	$ 54.2	$ 44.7
Related income tax benefit	5.0	5.0	5.6
Selling, general and administrative expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	54.8	46.7	38.4
Cost of sales
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	4.2	4.5	3.9
Research and development expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total compensation expense	$ 3.1	$ 3.0	$ 2.4

Consolidated Balance Sheets - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Current assets:
Cash and cash equivalents	$ 120.8	$ 138.2
Trade accounts receivable, net of allowance for credit losses of $31.3 at October 31, 2023 and $20.7 at October 31, 2022	609.7	557.8
Inventories (Note 1)	735.6	628.7
Prepaid expense and other current assets	238.8	208.9
Total current assets	1,704.9	1,533.6
Property, plant and equipment, net	1,632.6	1,432.9
Goodwill (Note 4)	3,624.5	3,609.7
Other intangibles, net (Note 4)	1,710.3	1,885.1
Deferred tax assets	2,349.5	2,443.1
Other assets	637.1	587.9
Total assets	11,658.9	11,492.3
Current liabilities:
Short-term debt (Note 5)	45.4	412.6
Accounts payable	261.9	248.8
Employee compensation and benefits	174.8	152.1
Deferred revenue	123.6	93.6
Other current liabilities	363.3	373.1
Total current liabilities	969.0	1,280.2
Long-term debt	2,523.8	2,350.8
Deferred tax liabilities	101.5	149.9
Long-term tax payable	90.2	113.2
Deferred revenue	184.2	198.3
Other liabilities	239.2	225.2
Total liabilities	4,107.9	4,317.6
Contingencies (Note 11)
Stockholders’ equity:
Preferred stock, $10 cents par value, 1.0 shares authorized, zero shares issued or outstanding	0.0	0.0
Common stock, $10 cents par value, 120.0 shares authorized, 53.9 issued and 49.5 outstanding at October 31, 2023 and 53.8 issued and 49.3 outstanding at October 31, 2022	5.4	5.4
Additional paid-in capital	1,833.4	1,765.5
Accumulated other comprehensive loss	(453.8)	(466.8)
Retained earnings	6,876.1	6,584.9
Treasury stock at cost: 4.4 shares at October 31, 2023 and 4.5 shares at October 31, 2022	(710.3)	(714.5)
Total Cooper stockholders' equity	7,550.8	7,174.5
Noncontrolling interests	0.2	0.2
Stockholders’ equity (Note 8)	7,551.0	7,174.7
Total liabilities and stockholders’ equity	$ 11,658.9	$ 11,492.3

Financial Derivatives and Hedging - Changes in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	$ 7,174.7	$ 6,942.0	$ 3,824.8
Amount recognized in other comprehensive income on interest rate swaps contracts, net of tax	25.7	79.7
Amount reclassified from other comprehensive income into earnings, net of tax	(32.7)	1.7
Ending balance	7,551.0	7,174.7	6,942.0
Accumulated Gain (Loss), Net, Cash Flow Hedge, Before Tax, Parent
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	124.5	17.2
Ending balance	115.1	124.5	17.2
Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent
AOCI Attributable To Parent, Before Reclassification And Tax [Roll Forward]
Beginning balance	94.4	13.1	(13.0)
Amount recognized in other comprehensive income on interest rate swap contracts, gross	33.7	105.1
Amount reclassified from other comprehensive income into earnings, gross	(43.1)	2.2
Ending balance	$ 87.4	$ 94.4	$ 13.1

- Definition

Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.

+ References

+ Details

Schedule II

12 Months Ended

Oct. 31, 2023

SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]

Schedule II

THE COOPER COMPANIES, INC. AND SUBSIDIARIES

VALUATION AND QUALIFYING ACCOUNTS

Three Years Ended October 31, 2023


(In millions)	Balance Beginning of Year	Additions	Reductions/ Charges	Balance at End of Year
Deferred income tax valuation allowance:
Year Ended October 31, 2023	60.1	2.6	(42.0)	20.7
Year Ended October 31, 2022	51.8	13.3	(5.0)	60.1
Year Ended October 31, 2021	45.3	8.8	(2.3)	51.8

Intangible Assets - Other Intangible Assets (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,916.1	$ 2,919.0
Accumulated Amortization	1,215.1	1,044.7
Intangible assets with definite lives, net	1,701.0	1,874.3
Intangible assets with indefinite lives, net	9.3	10.8
Total other intangibles, net	$ 1,710.3	1,885.1
Weighted-average Amortization Period (in years)	16 years
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 208.9	209.6
Accumulated Amortization	$ 81.1	62.4
Weighted-average Amortization Period (in years)	15 years
Composite intangible asset
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,061.9	1,061.9
Accumulated Amortization	$ 424.8	354.0
Weighted-average Amortization Period (in years)	15 years
Technology
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 494.5	504.1
Accumulated Amortization	$ 335.4	317.5
Weighted-average Amortization Period (in years)	13 years
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 1,099.2	1,092.7
Accumulated Amortization	$ 345.8	287.0
Weighted-average Amortization Period (in years)	19 years
License and distribution rights and other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 51.6	50.7
Accumulated Amortization	$ 28.0	$ 23.8
Weighted-average Amortization Period (in years)	11 years

Consolidated Statements of Stockholders' Equity - USD ($) $ in Millions	Total	Common Shares	Treasury Stock	Treasury Stock Par Net Value	Additional Paid-In Capital	Accumulated Other Comprehensive Income Loss	Retained Earnings	Noncontrolling Interests	Cumulative Effect, Period of Adoption, Adjustment	Cumulative Effect, Period of Adoption, Adjustment Retained Earnings
Common stock, beginning balance (in shares) at Oct. 31, 2020		49,100,000
Treasury stock, beginning balance (in shares) at Oct. 31, 2020			4,300,000
Beginning balance at Oct. 31, 2020	$ 3,824.8	$ 4.9	$ (617.3)	$ 0.4	$ 1,646.8	$ (472.0)	$ 3,261.8	$ 0.2	$ (1.4)	$ (1.4)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	2,944.7						2,944.7
Other comprehensive income (loss), net of tax	130.7					130.7
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		300,000
Issuance of common stock for stock plans, net and employee stock purchase plan	27.2		$ 2.5		24.6
Treasury stock repurchase (in shares)		100,000	100,000
Treasury stock repurchase	(24.8)		$ (24.8)
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	43.8				43.8
Common stock, ending balance (in shares) at Oct. 31, 2021		49,300,000
Treasury stock, ending balance (in shares) at Oct. 31, 2021			4,400,000
Ending balance at Oct. 31, 2021	6,942.0	$ 5.0	$ (639.6)	0.4	1,715.2	(341.3)	6,202.1	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	385.8						385.8
Other comprehensive income (loss), net of tax	(125.5)					(125.5)
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		100,000
Issuance of common stock for stock plans, net and employee stock purchase plan	$ 1.5		$ 3.6		(2.1)
Treasury stock repurchase (in shares)	191,200	100,000	100,000
Treasury stock repurchase	$ (78.5)		$ (78.5)
Dividends on common stock ($0.03 per share)	(3.0)						(3.0)
Share-based compensation expense	$ 52.4				52.4
Common stock, ending balance (in shares) at Oct. 31, 2022	49,300,000	49,300,000
Treasury stock, ending balance (in shares) at Oct. 31, 2022	4,500,000		4,500,000
Ending balance at Oct. 31, 2022	$ 7,174.7	$ 5.0	$ (714.5)	0.4	1,765.5	(466.8)	6,584.9	0.2
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	294.2						294.2
Other comprehensive income (loss), net of tax	13.0					13.0
Issuance of common stock for stock plans, net and employee stock purchase plan (in shares)		200,000	100,000
Issuance of common stock for stock plans, net and employee stock purchase plan	$ 11.3		$ 4.2		7.1
Treasury stock repurchase (in shares)	0
Dividends on common stock ($0.03 per share)	$ (3.0)						(3.0)
Share-based compensation expense	$ 60.8				60.8
Common stock, ending balance (in shares) at Oct. 31, 2023	49,500,000	49,500,000
Treasury stock, ending balance (in shares) at Oct. 31, 2023	4,400,000		4,400,000
Ending balance at Oct. 31, 2023	$ 7,551.0	$ 5.0	$ (710.3)	$ 0.4	$ 1,833.4	$ (453.8)	$ 6,876.1	$ 0.2

Financial Derivatives and Hedging (Tables)

12 Months Ended

Oct. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Derivative instruments recognized in condensed consolidated statements of income

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income:


Periods Ended October 31,
(In millions)		2023		2022		2021
Derivatives designated as cash flow hedges	Location of (Gain)/Loss Recognized on Derivatives
Interest rate swap contracts	Interest expense (income)	$	(43.1)	$	(2.3)	$	8.0

Changes in accumulated other comprehensive (loss) income

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	82.2		34.3		29.8		146.3
Tax effect	(0.2)		(8.2)		(7.2)		(15.6)

Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)
Gross change in value	$	(234.7)	$	107.4	$	36.6	$	(90.7)
Tax effect	—		(26.1)		(8.7)		(34.8)

Balance at October 31, 2022	$	(555.0)	$	94.4	$	(6.2)	$	(466.8)
Gross change in value	$	17.0	$	(9.4)	$	4.0	$	11.6

Tax effect	—		2.4		(1.0)		1.4
Balance at October 31, 2023	$	(538.0)	$	87.4	$	(3.2)	$	(453.8)

The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:


(In millions)	Amount
Balance gain as of October 31, 2021	$	17.2
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($79.7, net of tax)	105.1
Amount reclassified from other comprehensive income into earnings, gross ($1.7, net of tax)	2.2
Balance gain as of October 31, 2022	$	124.5
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($25.7, net of tax)	33.7
Amount reclassified from other comprehensive income into earnings, gross ($(32.7), net of tax)	(43.1)
Balance gain as of October 31, 2023	$	115.1

Operating Leases - Leases on the Consolidated Condensed Balance Sheet (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Operating Leases
Operating lease right-of-use assets	$ 241.5	$ 230.1
Operating Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Other assets	Other assets
Operating lease liabilities, current	$ 38.2	$ 35.5
Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Other current liabilities	Other current liabilities
Operating lease liabilities, non-current	$ 215.6	$ 205.5
Operating Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Other liabilities	Other liabilities
Total operating lease liabilities	$ 253.8	$ 241.0
Weighted-average remaining lease term (in years)	10 years	9 years 9 months 18 days
Weighted-average discount rate	4.00%	3.00%

Income Taxes

12 Months Ended

Oct. 31, 2023

Income Tax Disclosure [Abstract]

Income Taxes

Note 6. Income Taxes

In November 2020, the Company completed an intra-group transfer of certain intellectual property and related assets of CooperVision to a UK subsidiary as part of a group restructuring to establish headquarters operations in the UK. Determining fair value involved significant judgment related to future revenue growth, operating margins, and discount rates. The transfer resulted in a step-up of the UK tax-deductible basis in the intellectual property and goodwill, creating a temporary difference between the book basis and the tax basis of these assets. As a result, the Company recognized a deferred tax asset of $1,987.9 million, with a corresponding income tax benefit, during the first quarter of fiscal 2021. During the third quarter of fiscal 2021, the Company recognized a $536.7 million tax benefit related primarily to the remeasurement of this deferred tax asset caused by the UK enactment of a 25% corporate tax rate.

Components of income before income taxes:


Years Ended October 31, (In millions)	2023		2022		2021
Income before income taxes:
United States	$	(135.7)	$	31.4	$	(31.0)
Foreign	548.6		443.9		522.5
	$	412.9	$	475.3	$	491.5

Components of provision for income taxes:


Years Ended October 31, (In millions)	2023		2022		2021
Current:
Federal	$	37.3	$	10.2	$	21.0
State	3.7		3.8		1.3
Foreign	33.0		21.7		26.7
	74.0		35.7		49.0

Deferred:
Federal	(36.7)		10.5		(8.8)
State	(7.5)		(2.2)		(0.5)
Foreign	88.9		45.6		(2,492.9)
	44.7		53.9		(2,502.2)
Provision for income taxes	$	118.7	$	89.5	$	(2,453.2)

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes:


Years Ended October 31, (In millions)	2023		2022		2021
Provision for income taxes at United States statutory tax rate	$	86.7	$	99.8	$	103.2
(Decrease) increase in taxes resulting from:
Foreign earnings in jurisdictions with different tax rates	7.0		(22.3)		(43.6)
Foreign earnings subject to United States tax	34.3		21.1		25.4

Excess tax benefits from share-based compensation	(2.4)		(2.6)		(13.0)
Intra-group transfer to UK subsidiary	—		—		(1,987.8)
Remeasurement of deferred tax assets from UK rate change	—		—		(536.7)
Change in unrecognized tax benefits	—		(12.7)		(7.6)
State tax provision	(4.2)		5.0		0.8
Other, net	(2.7)		1.2		6.1
Provision for income taxes	$	118.7	$	89.5	$	(2,453.2)

Components of deferred tax assets and liabilities:


Years Ended October 31, (In millions)	2023		2022
Deferred tax assets:
Accounts receivable	$	7.5	$	4.9
Inventories	14.3		6.3
Accrued liabilities, reserves and compensation accruals	94.8		79.9
Foreign deferred tax assets	2,369.5		2,500.5
Share-based compensation	14.8		14.5
Net operating loss and tax credit carryforwards	24.3		19.6
Capitalized research and experimental expenses	23.6		15.4
Total gross deferred tax assets	2,548.8		2,641.1
Less: valuation allowance	(20.7)		(60.1)
Deferred tax assets	2,528.1		2,581.0
Deferred tax liabilities:
Tax deductible goodwill	(47.4)		(39.7)
Intangible assets	(132.4)		(153.8)
Plant and equipment	(51.2)		(48.8)
Foreign deferred tax liabilities	(49.0)		(45.5)


Total gross deferred tax liabilities	(280.0)		(287.8)
Net deferred tax assets	$	2,248.1	$	2,293.2

In assessing the realizability of deferred tax assets, the Company analyzes whether some or all deferred tax assets will not be realized. This analysis considers historical taxable income, the projected reversal of deferred tax liabilities, projected taxable income and tax planning strategies. Based upon this analysis, it is more likely than not the deferred tax assets, net of valuation allowance, will be realized. The decrease in valuation allowance is primarily related to foreign tax attributes.

At October 31, 2023, the Company had federal net operating loss carryforwards of $78.7 million and state net operating loss carryforwards of $87.1 million. Federal net operating loss carryforwards of $46.0 million expire on various dates between 2024 and 2037 and $32.7 million do not expire. The state net operating loss carryforwards expire on various dates between 2027 through 2044.

A tax benefit is recognized if it is more likely than not that a tax position will be sustained on its technical merits, based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority.

Changes in unrecognized tax benefits:


(In millions)
Balance at October 31, 2021	$	353.8
Decrease based on tax positions in prior fiscal years	(12.5)
Settlements	(0.2)
Lapses of statutes of limitations	(4.2)
Balance at October 31, 2022	$	336.9
Decrease based on tax positions in prior fiscal years	(0.5)
Increase based on tax positions in current fiscal year	2.0


Lapses of statutes of limitations	(6.9)

Balance at October 31, 2023	$	331.5

These tax benefits, if recognized, would reduce provision for income taxes for 2023, 2022 and 2021, by $323.2 million, $324.3 million, and $336.5 million, respectively. Interest and penalties related to unrecognized tax benefits are recognized in provision for income taxes. As of October 31, 2023, 2022 and 2021, accrued gross interest and penalties related to unrecognized tax benefits was $5.8 million, $5.4 million, and $6.4 million, respectively.

Included in the balance of unrecognized tax benefits at October 31, 2023, is $8.1 million related to tax positions for which it is reasonably possible that the total amounts could change during the next twelve months.

Filed tax returns are subject to examination by tax authorities in major tax jurisdictions after fiscal 2018, including the UK and the US.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Employee Benefits - Weighted-Average Asset Allocations by Asset Category (Details)	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	100.00%	100.00%	100.00%
Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	2.90%	2.00%	5.00%
Corporate common stock
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	26.00%	33.60%	31.60%
Equity mutual funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	39.10%	33.90%	32.80%
Balanced funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	2.40%	1.80%	1.40%
Alternative investments
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	0.70%	0.90%	1.00%
Bond mutual funds
Defined Benefit Plan, Plan Assets, Allocation [Line Items]
Asset allocation	28.90%	27.80%	28.20%

Income Taxes - Income Tax Provision (Benefit) (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Current:
Federal	$ 37.3	$ 10.2	$ 21.0
State	3.7	3.8	1.3
Foreign	33.0	21.7	26.7
Total current income tax expense (benefit)	74.0	35.7	49.0
Deferred:
Federal	(36.7)	10.5	(8.8)
State	(7.5)	(2.2)	(0.5)
Foreign	88.9	45.6	(2,492.9)
Total deferred income tax expense (benefit)	44.7	53.9	(2,502.2)
Provision for income taxes	$ 118.7	$ 89.5	$ (2,453.2)

Schedule II (Details) - SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance Beginning of Year	$ 60.1	$ 51.8	$ 45.3
Additions	2.6	13.3	8.8
Reductions/ Charges	(42.0)	(5.0)	(2.3)
Balance at End of Year	$ 20.7	$ 60.1	$ 51.8

Intangible Assets - Goodwill (Details) $ in Millions	12 Months Ended
Intangible Assets - Goodwill (Details) $ in Millions	Oct. 31, 2023 USD ($)
Goodwill [Roll Forward]
Balance, beginning	$ 3,609.7
Net changes	4.1
Foreign currency translation adjustment	10.7
Balance, ending	3,624.5
CooperVision
Goodwill [Roll Forward]
Balance, beginning	1,710.3
Net changes	7.7
Foreign currency translation adjustment	29.6
Balance, ending	1,747.6
CooperSurgical
Goodwill [Roll Forward]
Balance, beginning	1,899.4
Net changes	(3.6)
Foreign currency translation adjustment	(18.9)
Balance, ending	$ 1,876.9

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

Business Segment Information - Information by Geographical Area by Country of Domicile (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Segment Reporting Information [Line Items]
Net sales	$ 3,593.2	$ 3,308.4	$ 2,922.5
Operating income	533.1	507.6	505.8
Long-lived assets	1,632.6	1,432.9	1,347.6
United States
Segment Reporting Information [Line Items]
Net sales	1,812.2	1,638.5	1,339.2
Europe
Segment Reporting Information [Line Items]
Net sales	1,041.2	987.2	957.9
Rest of World
Segment Reporting Information [Line Items]
Net sales	739.8	682.7	625.4
Geography Eliminations \| United States
Segment Reporting Information [Line Items]
Net sales	(563.1)	(514.4)	(494.9)
Geography Eliminations \| Europe
Segment Reporting Information [Line Items]
Net sales	(1,016.7)	(897.3)	(815.1)
Geography Eliminations \| Rest of World
Segment Reporting Information [Line Items]
Net sales	(1,579.8)	(1,411.7)	(1,310.0)
Reportable Geographical Components \| United States
Segment Reporting Information [Line Items]
Net sales	2,375.3	2,152.9	1,834.1
Operating income	0.0	71.8	(26.8)
Long-lived assets	1,027.6	856.1	737.5
Reportable Geographical Components \| Europe
Segment Reporting Information [Line Items]
Net sales	2,057.9	1,884.5	1,773.0
Operating income	516.2	403.8	416.2
Long-lived assets	325.9	310.8	377.2
Eliminations, Corporate and Reconciling Items \| Rest of World
Segment Reporting Information [Line Items]
Net sales	(840.0)	(729.0)	(684.6)
Operating income	16.9	32.0	116.4
Long-lived assets	$ 279.1	$ 266.0	$ 232.9

Employee Benefits - Other Changes in Plan Assets and Benefit Obligations Recognized in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Other changes in plan assets and benefit obligations recognized in other comprehensive income:
Net (gain) loss	$ (4.0)	$ (34.1)	$ (24.4)
Amortizations of net gain	0.0	(2.5)	(5.4)
Total recognized in other comprehensive (income) loss	(4.0)	(36.6)	(29.8)
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$ 2.8	$ (26.2)	$ (15.2)

Intangible Assets (Tables)

12 Months Ended

Oct. 31, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of goodwill


(In millions)	CooperVision		CooperSurgical		Total




Balance at October 31, 2022	$	1,710.3	$	1,899.4	$	3,609.7
Net changes	7.7		(3.6)		4.1

Foreign currency translation adjustment	29.6		(18.9)		10.7
Balance at October 31, 2023	$	1,747.6	$	1,876.9	$	3,624.5

Schedule of finite-lived intangible assets

Other Intangible Assets


	October 31, 2023				October 31, 2022
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted-average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	208.9	$	81.1	$	209.6	$	62.4	15
Composite intangible asset	1,061.9		424.8		1,061.9		354.0		15
Technology	494.5		335.4		504.1		317.5		13
Customer relationships	1,099.2		345.8		1,092.7		287.0		19
License and distribution rights and other	51.6		28.0		50.7		23.8		11
	2,916.1		$	1,215.1	2,919.0		$	1,044.7	16
Less: accumulated amortization and translation	1,215.1				1,044.7
Intangible assets with definite lives, net	$	1,701.0			$	1,874.3
Intangible assets with indefinite lives, net (1)	9.3				10.8
Total other intangibles, net	$	1,710.3			$	1,885.1

(1) Intangible assets with indefinite lives include technology and trademarks.

Schedule of indefinite-lived intangible assets

Other Intangible Assets


	October 31, 2023				October 31, 2022
(In millions)	Gross Carrying Amount		Accumulated Amortization		Gross Carrying Amount		Accumulated Amortization		Weighted-average Amortization Period (in years)
Intangible assets with definite lives:
Trademarks	$	208.9	$	81.1	$	209.6	$	62.4	15
Composite intangible asset	1,061.9		424.8		1,061.9		354.0		15
Technology	494.5		335.4		504.1		317.5		13
Customer relationships	1,099.2		345.8		1,092.7		287.0		19
License and distribution rights and other	51.6		28.0		50.7		23.8		11
	2,916.1		$	1,215.1	2,919.0		$	1,044.7	16
Less: accumulated amortization and translation	1,215.1				1,044.7
Intangible assets with definite lives, net	$	1,701.0			$	1,874.3
Intangible assets with indefinite lives, net (1)	9.3				10.8
Total other intangibles, net	$	1,710.3			$	1,885.1

(1) Intangible assets with indefinite lives include technology and trademarks.

Remaining amortization expenses for intangible assets with definite lives

As of October 31, 2023, the estimate of future amortization expenses for intangible assets with definite lives is as follows:


Fiscal years:	(In millions)
2024	$	179.5
2025	169.5
2026	162.0
2027	147.7
2028	143.2
Thereafter	899.1
Total remaining amortization for intangible assets with definite lives	$	1,701.0

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Statement of Comprehensive Income [Abstract]
Cash flow hedges, tax provision (benefit)	$ (2.4)	$ 26.1	$ 8.2
Change in minimum pension liability, tax provision (benefit)	$ 1.0	$ 8.7	$ 7.2

Financing Arrangements - Total Debt (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Short-term Debt
Short-term debt	$ 44.4	$ 395.7
Financing lease liabilities	$ 1.0	$ 16.9
Finance Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]	Short-term debt	Short-term debt
Short-term debt	$ 45.4	$ 412.6
Long-term Debt
Less: unamortized debt issuance cost	(2.4)	(3.1)
Long-term debt, excluding financing leases	2,520.4	2,347.1
Financing lease liabilities	$ 3.4	$ 3.7
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible Enumeration]	Long-term debt	Long-term debt
Long-term debt	$ 2,523.8	$ 2,350.8
Total debt	2,569.2	2,763.4
Term loans
Long-term Debt
Long-term debt, gross	2,350.0	2,350.0
Other
Long-term Debt
Long-term debt, gross	0.2	0.2
Revolving Credit Facility \| Line of Credit
Long-term Debt
Long-term debt, gross	172.6	0.0
Overdraft and other credit facilities
Short-term Debt
Short-term debt	44.4	57.7
Term loans
Short-term Debt
Short-term debt	$ 0.0	$ 338.0

Audit Information	12 Months Ended
Audit Information	Oct. 31, 2023
Audit Information [Abstract]
Auditor Name	KPMG LLP
Auditor Location	San Francisco, CA
Auditor Firm ID	185

Employee Benefits (Tables)

12 Months Ended

Oct. 31, 2023

Retirement Benefits [Abstract]

Changes in benefit obligation, changes in plan assets and funded status

The following table sets forth the Plan's benefit obligations and fair value of the Plan assets at October 31, 2023, 2022 and 2021 and the funded status of the Plan and net periodic pension costs for each of the years in the three-year periods ended October 31, 2023. The net amounts recognized in the Consolidated Balance Sheets consist of noncurrent liabilities. The accumulated benefit obligation was $131.5 million, $134.9 million and $207.6 million for the years ended October 31, 2023, 2022 and 2021.

Retirement Income Plan


Years Ended October 31, (In millions)	2023		2022		2021
Change in benefit obligation
Benefit obligation, beginning of year	$	148.0	$	230.9	$	218.8
Service cost	10.0		18.3		17.2
Interest cost	7.9		5.1		4.4
Benefits paid	(10.5)		(13.1)		(11.5)

Actuarial (gain)/loss	(10.9)		(93.2)		2.0
Benefit obligation, end of year	$	144.5	$	148.0	$	230.9
Change in plan assets
Fair value of plan assets, beginning of year	$	142.9	$	199.5	$	159.5
Actual return on plan assets	4.1		(43.5)		38.8
Employer contributions	1.1		—		12.7
Benefits paid	(10.5)		(13.1)		(11.5)
Fair value of plan assets, end of year	$	137.6	$	142.9	$	199.5
Funded status at end of year	$	(6.9)	$	(5.1)	$	(31.4)

Amounts recognized in accumulated other comprehensive Income


Years Ended October 31, (In millions)	2023		2022		2021
Amounts recognized in accumulated other comprehensive income consist of:


Net loss	$	4.1	$	8.0	$	44.4
Accumulated other comprehensive income	$	4.1	$	8.0	$	44.4

Reconciliation of prepaid (accrued) pension cost


Years Ended October 31, (In millions)	2023		2022		2021
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$	(2.9)	$	(13.0)	$	(14.8)
Net periodic benefit cost	6.8		10.1		14.5
Contributions made during the year	(1.1)		—		(12.7)

(Prepaid)/Accrued pension cost at fiscal year end	$	2.8	$	(2.9)	$	(13.0)

Components of net periodic pension costs and other amounts recognized in other comprehensive income


Years Ended October 31, (In millions)	2023		2022		2021
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Net periodic benefit cost:
Service cost	$	10.0	$	18.3	$	17.2
Interest cost	7.9		5.1		4.4
Expected return on plan assets	(11.1)		(15.5)		(12.5)


Recognized actuarial loss	—		2.2		5.4
Net periodic pension cost	$	6.8	$	10.1	$	14.5

Other changes in plan assets and benefit obligations recognized in other comprehensive income


Years Ended October 31, (In millions)	2023		2022		2021
Other changes in plan assets and benefit obligations recognized in other comprehensive income:


Net (gain) loss	$	(4.0)	$	(34.1)	$	(24.4)


Amortizations of net gain	—		(2.5)		(5.4)



Total recognized in other comprehensive (income) loss	$	(4.0)	$	(36.6)	$	(29.8)
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$	2.8	$	(26.2)	$	(15.2)

Weighted-average assumptions used in computing net periodic pension cost and projected benefit obligation


Years Ended October 31,	2023		2022		2021
Weighted-average assumptions used in computing the net periodic pension cost and projected benefit obligation at year end:
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	5.74	%	2.76	%	2.78	%
Service Cost	5.77	%	2.79	%	2.86	%
Interest Cost	5.51	%	2.28	%	2.07	%
Discount rate for determining benefit obligations at year end	6.22	%	5.74	%	2.76	%
Rate of compensation increase for determining expense	3.60	%	3.60	%	3.60	%
Rate of compensation increase for determining benefit obligations at year end	3.60	%	3.60	%	3.60	%
Expected rate of return on plan assets for determining net periodic pension cost	8.00	%	8.00	%	8.00	%
Expected rate of return on plan assets at year end	8.00	%	8.00	%	8.00	%
Measurement date for determining assets and benefit obligations at year end	10/31/2023		10/31/2022		10/31/2021

Weighted-average asset allocations and fair value measurement of plan assets

Plan Assets

Weighted-average asset allocations at year end, by asset category are as follows:


Years Ended October 31,	2023		2022		2021
Asset category
Cash and cash equivalents	2.9	%	2.0	%	5.0	%
Corporate common stock	26.0	%	33.6	%	31.6	%
Equity mutual funds	39.1	%	33.9	%	32.8	%
Balanced funds	2.4	%	1.8	%	1.4	%
Alternative investments	0.7	%	0.9	%	1.0	%


Bond mutual funds	28.9	%	27.8	%	28.2	%
Total	100.0	%	100.0	%	100.0	%

As of the measurement date of October 31, 2023, the fair value measurement of plan assets is as follows:


(In millions)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Asset category
Cash and cash equivalents	$	3.9	$	3.9	$	—	$	—
Corporate common stock	35.8		35.8		—		—
Equity mutual funds	53.9		53.9		—		—
Balanced Funds	3.3		3.3		—		—
Alternative investments	0.9		0.9		—		—
Fixed income	39.8		15.8		24.0		—


Total	$	137.6	$	113.6	$	24.0	$	—

Estimated future benefit payments

Estimated Future Benefit Payments


Years (In millions)
2024	$	10.9
2025	$	11.0
2026	$	10.3
2027	$	11.2
2028	$	12.3
2029-2033	$	65.9

Income Taxes - Reconciliation between the Expected Provision for Income taxes at the US Federal Statutory Rate and the Provision for Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Jul. 31, 2021	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Income Tax Disclosure [Abstract]
Provision for income taxes at United States statutory tax rate		$ 86.7	$ 99.8	$ 103.2
Foreign earnings in jurisdictions with different tax rates		7.0	(22.3)	(43.6)
Foreign earnings subject to United States tax		34.3	21.1	25.4
Excess tax benefits from share-based compensation		(2.4)	(2.6)	(13.0)
Intra-group transfer to UK subsidiary		0.0	0.0	(1,987.8)
Remeasurement of deferred tax assets from UK rate change	$ (536.7)	0.0	0.0	(536.7)
Change in unrecognized tax benefits		0.0	(12.7)	(7.6)
State tax provision		(4.2)	5.0	0.8
Other, net		(2.7)	1.2	6.1
Provision for income taxes		$ 118.7	$ 89.5	$ (2,453.2)

Earnings Per Share - Stock Options to Purchase Common Stock and Restricted Stock Units Not Included in Diluted Earnings Per Share Due to Antidilutive Effect (Details) - $ / shares shares in Thousands	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Range of exercise prices, lower limit (in dollars per share)	$ 300.12	$ 300.12	$ 345.74
Range of exercise prices, higher limit (in dollars per share)	$ 406.17	$ 406.17	$ 345.74
Stock Options
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock option shares and restricted stock units excluded (in shares)	311	227	107
Restricted Stock Units (RSUs)
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Stock option shares and restricted stock units excluded (in shares)	15	87	2

Stock Plans - Non-Vested RSUs (Details) - Restricted Stock Units (RSUs)	12 Months Ended
	Oct. 31, 2023 $ / shares shares
Number of Shares
Nonvested RSUs, beginning balance (in shares) \| shares	289,238
Granted (in shares) \| shares	145,655
Vested and issued (in shares) \| shares	(107,403)
Forfeited or expired (in shares) \| shares	(37,461)
Nonvested RSUs, ending balance (in shares) \| shares	290,029
Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs, beginning balance (in dollars per share) \| $ / shares	$ 340.68
Granted (in dollars per share) \| $ / shares	335.32
Vested and issued (in dollars per share) \| $ / shares	320.22
Forfeited or exercised (in dollars per share) \| $ / shares	344.72
Non-vested RSUs, ending balance (in dollars per share) \| $ / shares	$ 345.03

Employee Benefits - Estimated Future Benefit Payments (Details) $ in Millions	Oct. 31, 2023 USD ($)
Defined Benefit Plan, Expected Future Benefit Payment [Abstract]
2024	$ 10.9
2025	11.0
2026	10.3
2027	11.2
2028	12.3
2029-2033	$ 65.9

Intangible Assets - Estimated Amortization Expenses for Intangible Assets with Definite Lives (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
2024	$ 179.5
2025	169.5
2026	162.0
2027	147.7
2028	143.2
Thereafter	899.1
Intangible assets with definite lives, net	$ 1,701.0	$ 1,874.3

Consolidated Statements of Stockholders' Equity (Parenthetical) - $ / shares	6 Months Ended				12 Months Ended
	Oct. 31, 2023	Apr. 30, 2023	Oct. 31, 2022	Apr. 30, 2022	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Statement of Stockholders' Equity [Abstract]
Dividends on common stock (in dollars per share)	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03	$ 0.03

Employee Benefits - Fair Value Measurement of Plan Assets (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021	Oct. 31, 2020
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	$ 137.6	$ 142.9	$ 199.5	$ 159.5
Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	113.6
Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	24.0
Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Cash and cash equivalents
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	3.9
Cash and cash equivalents \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	3.9
Cash and cash equivalents \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Cash and cash equivalents \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Corporate common stock
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	35.8
Corporate common stock \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	35.8
Corporate common stock \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Corporate common stock \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Equity mutual funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	53.9
Equity mutual funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	53.9
Equity mutual funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Equity mutual funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Balanced funds
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	3.3
Balanced funds \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	3.3
Balanced funds \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Balanced funds \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Alternative investments
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.9
Alternative investments \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.9
Alternative investments \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Alternative investments \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	0.0
Fixed Income Investments
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	39.8
Fixed Income Investments \| Quoted Prices in Active Markets for Identical Assets (Level 1)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	15.8
Fixed Income Investments \| Significant Observable Inputs (Level 2)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	24.0
Fixed Income Investments \| Significant Unobservable Inputs (Level 3)
Defined Benefit Plan, Plan Assets, Category [Line Items]
Fair value of plan assets	$ 0.0

Financing Arrangements - Narrative (Details) - USD ($)	Dec. 17, 2021	Nov. 02, 2021	Apr. 01, 2020	Oct. 31, 2023	Oct. 31, 2022
Term Loan Agreement 2021, 364 Day \| Term loans
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt term		364 days
Debt Instrument, Face Amount		$ 840,000,000
Line of Credit \| Term Loan Facility 2021
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount	$ 1,500,000,000
Potential additional borrowing capacity	$ 1,125,000,000
Debt outstanding				$ 1,500,000,000
Interest rate				6.41%
Line of Credit \| Term Loan Facility 2021 \| Secured Overnight Financing Rate (SOFR)
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	1.00%
Line of Credit \| Term Loan Facility 2021 \| Fed Funds Effective Rate Overnight Index Swap Rate
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.50%
Line of Credit \| Term Loan Facility, 2021 Base Rate Loans \| Secured Overnight Financing Rate (SOFR)
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.00%
Line of Credit \| Term Loan Facility 2021, Adjusted LIBOR Rate Loans \| Secured Overnight Financing Rate (SOFR)
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate	0.75%
Revolving Credit Facility \| Credit Agreement 2020 \| Line of Credit
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 1,290,000,000
Debt outstanding				$ 172,600,000
Interest rate				6.41%
Proceeds from line of credit			$ 445,000,000
Revolving Credit Facility \| Credit Agreement 2020 \| Line of Credit \| Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.10%
Revolving Credit Facility \| Credit Agreement 2020 \| Line of Credit \| Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Commitment fee percentage			0.20%
Revolving Credit Facility \| European Credit Facilities \| Line of Credit
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount				$ 32,900,000	$ 30,700,000
Debt outstanding				$ 700,000
Weighted average interest rate				7.82%
Revolving Credit Facility \| Asian Pacific Credit Facilities - Yen-Denominated \| Line of Credit
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount				$ 74,300,000	$ 73,000,000
Debt outstanding				$ 41,400,000
Weighted average interest rate				0.40%
Term Loan Facility 2020 \| Credit Agreement 2020 \| Line of Credit
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Aggregate principal amount			$ 850,000,000
Debt outstanding				$ 850,000,000
Interest rate				6.41%
Proceeds from line of credit			850,000,000
Revolving Credit Facility And Term Loan Facility 2020 \| Credit Agreement 2020 \| Line of Credit
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Potential additional borrowing capacity			$ 1,605,000,000
Revolving Credit Facility And Term Loan Facility 2020 \| Credit Agreement 2020 \| Secured Overnight Financing Rate (SOFR) \| Line of Credit \| Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.75%
Revolving Credit Facility And Term Loan Facility 2020 \| Credit Agreement 2020 \| Secured Overnight Financing Rate (SOFR) \| Line of Credit \| Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			1.50%
Revolving Credit Facility And Term Loan Facility 2020 \| Credit Agreement 2020 \| Base Rate \| Line of Credit \| Minimum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.00%
Revolving Credit Facility And Term Loan Facility 2020 \| Credit Agreement 2020 \| Base Rate \| Line of Credit \| Maximum
Schedule of Long Term And Short Term Debt Instruments [Line Items]
Debt instrument, basis spread on variable rate			0.50%

Operating Leases

12 Months Ended

Oct. 31, 2023

Leases [Abstract]

Operating Leases

Note 2. Operating Leases

The following table presents information about leases on the Consolidated Balance Sheets:


October 31, (In millions)	2023		2022
Operating Leases
Operating lease right-of-use assets	$	241.5	$	230.1

Operating lease liabilities, current	38.2		35.5
Operating lease liabilities, non-current	215.6		205.5
Total operating lease liabilities	$	253.8	$	241.0

Weighted-average remaining lease term (in years)	10.0		9.8
Weighted-average discount rate	4%		3%

Operating lease expense for the fiscal years ended October 31, 2023, 2022 and 2021 was $48.1 million, $45.0 million and $44.1 million.

Maturity of Lease Liabilities

The minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of October 31, 2023 are:


(In millions)
2024	46.4
2025	41.6
2026	37.7
2027	32.8
2028	26.8
Thereafter	123.4
Total lease payments	$	308.7
Less: interest	54.9
Present value of lease liabilities	$	253.8

Income Taxes (Tables)

12 Months Ended

Oct. 31, 2023

Income Tax Disclosure [Abstract]

Income before income taxes

Components of income before income taxes:


Years Ended October 31, (In millions)	2023		2022		2021
Income before income taxes:
United States	$	(135.7)	$	31.4	$	(31.0)
Foreign	548.6		443.9		522.5
	$	412.9	$	475.3	$	491.5

Provision for income taxes

Components of provision for income taxes:


Years Ended October 31, (In millions)	2023		2022		2021
Current:
Federal	$	37.3	$	10.2	$	21.0
State	3.7		3.8		1.3
Foreign	33.0		21.7		26.7
	74.0		35.7		49.0

Deferred:
Federal	(36.7)		10.5		(8.8)
State	(7.5)		(2.2)		(0.5)
Foreign	88.9		45.6		(2,492.9)
	44.7		53.9		(2,502.2)
Provision for income taxes	$	118.7	$	89.5	$	(2,453.2)

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes

Reconciliation between the expected provision for income taxes at the US federal statutory rate and the provision for income taxes:


Years Ended October 31, (In millions)	2023		2022		2021
Provision for income taxes at United States statutory tax rate	$	86.7	$	99.8	$	103.2
(Decrease) increase in taxes resulting from:
Foreign earnings in jurisdictions with different tax rates	7.0		(22.3)		(43.6)
Foreign earnings subject to United States tax	34.3		21.1		25.4

Excess tax benefits from share-based compensation	(2.4)		(2.6)		(13.0)
Intra-group transfer to UK subsidiary	—		—		(1,987.8)
Remeasurement of deferred tax assets from UK rate change	—		—		(536.7)
Change in unrecognized tax benefits	—		(12.7)		(7.6)
State tax provision	(4.2)		5.0		0.8
Other, net	(2.7)		1.2		6.1
Provision for income taxes	$	118.7	$	89.5	$	(2,453.2)

Deferred tax assets and liabilities

Components of deferred tax assets and liabilities:


Years Ended October 31, (In millions)	2023		2022
Deferred tax assets:
Accounts receivable	$	7.5	$	4.9
Inventories	14.3		6.3
Accrued liabilities, reserves and compensation accruals	94.8		79.9
Foreign deferred tax assets	2,369.5		2,500.5
Share-based compensation	14.8		14.5
Net operating loss and tax credit carryforwards	24.3		19.6
Capitalized research and experimental expenses	23.6		15.4
Total gross deferred tax assets	2,548.8		2,641.1
Less: valuation allowance	(20.7)		(60.1)
Deferred tax assets	2,528.1		2,581.0
Deferred tax liabilities:
Tax deductible goodwill	(47.4)		(39.7)
Intangible assets	(132.4)		(153.8)
Plant and equipment	(51.2)		(48.8)
Foreign deferred tax liabilities	(49.0)		(45.5)


Total gross deferred tax liabilities	(280.0)		(287.8)
Net deferred tax assets	$	2,248.1	$	2,293.2

Changes in unrecognized tax benefits

Changes in unrecognized tax benefits:


(In millions)
Balance at October 31, 2021	$	353.8
Decrease based on tax positions in prior fiscal years	(12.5)
Settlements	(0.2)
Lapses of statutes of limitations	(4.2)
Balance at October 31, 2022	$	336.9
Decrease based on tax positions in prior fiscal years	(0.5)
Increase based on tax positions in current fiscal year	2.0


Lapses of statutes of limitations	(6.9)

Balance at October 31, 2023	$	331.5

Operating Leases - Minimum Rental Payments Required Under Operating Leases (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Leases [Abstract]
2024	$ 46.4
2025	41.6
2026	37.7
2027	32.8
2028	26.8
Thereafter	123.4
Total lease payments	308.7
Less: interest	54.9
Present value of lease liabilities	$ 253.8	$ 241.0

Stockholders' Equity

12 Months Ended

Oct. 31, 2023

Stockholders' Equity Note [Abstract]

Stockholders' Equity

Note 8. Stockholders’ Equity

Analysis of Changes in Accumulated Other Comprehensive Income (Loss):


(In millions)	Foreign Currency Translation Adjustment		Derivatives		Minimum Pension Liability		Total
Balance at October 31, 2020	$	(402.3)	$	(13.0)	$	(56.7)	$	(472.0)
Gross change in value	82.2		34.3		29.8		146.3
Tax effect	(0.2)		(8.2)		(7.2)		(15.6)

Balance at October 31, 2021	$	(320.3)	$	13.1	$	(34.1)	$	(341.3)
Gross change in value	$	(234.7)	$	107.4	$	36.6	$	(90.7)
Tax effect	—		(26.1)		(8.7)		(34.8)

Balance at October 31, 2022	$	(555.0)	$	94.4	$	(6.2)	$	(466.8)
Gross change in value	$	17.0	$	(9.4)	$	4.0	$	11.6

Tax effect	—		2.4		(1.0)		1.4
Balance at October 31, 2023	$	(538.0)	$	87.4	$	(3.2)	$	(453.8)

Share Repurchases

In December 2011, the Company's Board of Directors authorized the 2012 Program and through subsequent amendments, the most recent in March 2017, the total repurchase authorization was increased from $500.0 million to $1.0 billion of the Company's common stock. This program has no expiration date and may be discontinued at any time. Purchases under the 2012 Program are subject to a review of the circumstances in place at the time and may be made from time to time as permitted by securities laws and other legal requirements. As of October 31, 2023, $256.4 million remained authorized for repurchase under the program.

During the year ended October 31, 2023, there were no share repurchases under the 2012 Program. During the year ended October 31, 2022, the Company repurchased 191.2 thousand shares of its common stock for $78.5 million, at an average purchase price of $410.41 per share.

Dividends

In fiscal 2023 and 2022, the Company declared regular dividends of 6 cents per share (a semiannual dividend of 3 cents per share) and paid a total of $3.0 million in each fiscal year. In December 2023, our Board of Directors decided to end the declaration of the semiannual dividend.

Subsequent Event

On December 7, 2023, we announced that our Board of Directors had approved a four-for-one stock split of our outstanding shares of common stock which we expect to be effected as of February 16, 2024.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

Earnings Per Share (Tables)

12 Months Ended

Oct. 31, 2023

Earnings Per Share [Abstract]

Schedule of earnings per share


Years Ended October 31,
(In millions, except for earnings per share)	2023		2022		2021
Net income	$	294.2	$	385.8	$	2,944.7
Basic:
Weighted-average common shares	49.5		49.3		49.2
Basic earnings per share	$	5.94	$	7.83	$	59.80
Diluted:
Weighted-average common shares	49.5		49.3		49.2
Effect of dilutive stock plans	0.3		0.4		0.6
Diluted weighted-average common shares	49.8		49.7		49.8
Diluted earnings per share	$	5.91	$	7.76	$	59.16

Stock options to purchase common stock and restricted stock units not included in diluted earnings per share calculation due to antidilutive effect


Years Ended October 31,
(In thousands, except exercise prices)	2023	2022	2021
Stock option shares excluded	311	227	107
Exercise prices	$300.12 - $406.17	$300.12 - $406.17	$	345.74
Restricted stock units excluded	15	87	2

Operating Leases (Tables)

12 Months Ended

Oct. 31, 2023

Leases [Abstract]

Leases on the Consolidated Condensed Balance Sheet

The following table presents information about leases on the Consolidated Balance Sheets:


October 31, (In millions)	2023		2022
Operating Leases
Operating lease right-of-use assets	$	241.5	$	230.1

Operating lease liabilities, current	38.2		35.5
Operating lease liabilities, non-current	215.6		205.5
Total operating lease liabilities	$	253.8	$	241.0

Weighted-average remaining lease term (in years)	10.0		9.8
Weighted-average discount rate	4%		3%

Minimum rental payments required under operating leases

The minimum rental payments required under operating leases that have initial or remaining noncancellable lease terms in excess of one year as of October 31, 2023 are:


(In millions)
2024	46.4
2025	41.6
2026	37.7
2027	32.8
2028	26.8
Thereafter	123.4
Total lease payments	$	308.7
Less: interest	54.9
Present value of lease liabilities	$	253.8

Business Segment Information - Business Segment Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Segment Reporting Information [Line Items]
Net sales	$ 3,593,200	$ 3,308,400	$ 2,922,500
Operating income (loss)	533,100	507,600	505,800
Interest expense	105,300	57,300	23,100
Other expense (income), net	14,900	(25,000)	(8,800)
Income before income taxes	412,900	475,300	491,500
Identifiable assets	11,658,900	11,492,300	9,606,200
Depreciation expense	181,500	166,600	163,200
Amortization expense	186,200	179,500	146,100
Capital expenditures	392,500	242,000	214,400
CooperVision
Segment Reporting Information [Line Items]
Net sales	2,423,700	2,243,300	2,152,000
CooperSurgical
Segment Reporting Information [Line Items]
Net sales	1,169,500	1,065,100	770,500
Operating Segments \| CooperVision
Segment Reporting Information [Line Items]
Net sales	2,423,700	2,243,300	2,152,000
Operating income (loss)	587,700	494,300	481,300
Identifiable assets	7,044,000	6,778,900	6,965,900
Depreciation expense	156,900	144,500	148,300
Amortization expense	32,900	32,300	35,700
Capital expenditures	364,400	223,000	190,000
Operating Segments \| CooperSurgical
Segment Reporting Information [Line Items]
Net sales	1,169,500	1,065,100	770,500
Operating income (loss)	16,100	67,100	71,800
Identifiable assets	4,351,800	4,407,800	2,395,600
Depreciation expense	24,600	22,100	14,900
Amortization expense	153,300	147,200	110,400
Capital expenditures	28,100	19,000	24,400
Corporate
Segment Reporting Information [Line Items]
Net sales	0	0	0
Operating income (loss)	(70,700)	(53,800)	(47,300)
Identifiable assets	263,100	305,600	244,700
Depreciation expense	0	0	0
Amortization expense	0	0	0
Capital expenditures	$ 0	$ 0	$ 0

Label	Element	Value
Accounting Standards Update [Extensible Enumeration]	us-gaap_AccountingStandardsUpdateExtensibleList	Accounting Standards Update 2016-13 [Member]
Common Stock, Excluding Treasury Stock Par Net Value [Member]
Stock Issued During Period, Value, New Issues	us-gaap_StockIssuedDuringPeriodValueNewIssues	$ 100,000

- Definition

Indicates amendment to accounting standards.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 50
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147477123/405-50-65-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 13
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482477/820-10-65-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482477/820-10-65-13

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-5

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480528/815-20-65-6

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 832
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483482/832-10-65-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 832
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483482/832-10-65-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479845/805-20-65-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479845/805-20-65-3

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479845/805-20-65-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 5
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479832/842-10-65-5

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 848
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)(3)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483550/848-10-65-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 105
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479343/105-10-65-6

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (g)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (h)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480016/944-40-65-2

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 43: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 44: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 45: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 8
-Subparagraph (d)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482615/740-10-65-8

Reference 46: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 47: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 48: http://www.xbrl.org/2003/role/disclosureRef
-Topic 326
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 4
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479654/326-10-65-4

Reference 49: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 50: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 51: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 15
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480336/718-10-65-15

Reference 52: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 53: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 54: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 55: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 56: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 57: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 58: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 65
-Paragraph 6
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482833/825-10-65-6

Reference 59: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 60: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 61: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 62: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 63: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 64: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 65: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 66: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 67: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 68: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (e)(4)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 69: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 70: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 71: http://www.xbrl.org/2003/role/disclosureRef
-Topic 310
-SubTopic 20
-Name Accounting Standards Codification
-Section 65
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481925/310-20-65-2

Reference 72: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

+ Details

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

Stock Plans (Tables)

12 Months Ended

Oct. 31, 2023

Share-Based Payment Arrangement [Abstract]

Compensation expense and related income tax benefit for share-based awards

The compensation expense and related income tax benefit recognized in our Consolidated Statements of Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:


October 31,
(In millions)	2023		2022		2021
Selling, general and administrative expense	$	54.8	$	46.7	$	38.4
Cost of sales	4.2		4.5		3.9
Research and development expense	3.1		3.0		2.4
Total compensation expense	$	62.1	$	54.2	$	44.7
Related income tax benefit	$	5.0	$	5.0	$	5.6

Assumptions used in estimating fair value of stock options award granted


Years Ended October 31,	2023		2022		2021
Expected life	4.5 years		4.1 years		4.0 years
Expected volatility	29.5	%	25.8	%	30.3	%
Risk-free interest rate	3.8	%	1.1	%	0.3	%
Dividend yield	0.02	%	0.02	%	0.02	%

Schedule of stock option plans

The activity and status of our stock option plans are summarized below:


	Number of Shares	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at October 31, 2022	1,063,843	$	264.85
Granted	86,241	$	329.83
Exercised	(71,808)	$	155.45
Forfeited or expired	(720)	$	337.72
Outstanding at October 31, 2023	1,077,556	$	277.29	5.36	$	53,510,367
Vested and expected to vest at October 31, 2023	1,059,841	$	276.11	5.32	$	53,475,275
Vested and exercisable at October 31, 2023	729,591	$	248.34	4.38	$	50,797,891

Schedule of non-vested RSUs

The status of our non-vested RSUs is summarized below:


	Number of Shares	Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs at October 31, 2022	289,238	$	340.68
Granted	145,655	$	335.32
Vested and issued	(107,403)	$	320.22
Forfeited or expired	(37,461)	$	344.72
Non-vested RSUs at October 31, 2023	290,029	$	345.03

Consolidated Statements of Income - USD ($) shares in Millions, $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Income Statement [Abstract]
Net sales	$ 3,593.2	$ 3,308.4	$ 2,922.5
Cost of sales	1,235.3	1,168.8	966.7
Gross profit	2,357.9	2,139.6	1,955.8
Selling, general and administrative expense	1,501.2	1,342.2	1,211.2
Research and development expense	137.4	110.3	92.7
Amortization of intangibles	186.2	179.5	146.1
Operating income	533.1	507.6	505.8
Interest expense	105.3	57.3	23.1
Other expense (income)	14.9	(25.0)	(8.8)
Income before income taxes	412.9	475.3	491.5
Provision for income taxes (Note 6)	118.7	89.5	(2,453.2)
Net income	$ 294.2	$ 385.8	$ 2,944.7
Earnings per share (Note 7)
Basic (in dollars per share)	$ 5.94	$ 7.83	$ 59.80
Diluted (in dollars per share)	$ 5.91	$ 7.76	$ 59.16
Number of shares used to compute earnings per share:
Basic (in shares)	49.5	49.3	49.2
Diluted (in shares)	49.8	49.7	49.8

Organization and Significant Accounting Policies (Policies)	12 Months Ended
	Oct. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Principles of Consolidation	Principles of Consolidation The financial statements in this report include the results of all of Cooper's consolidated entities. All significant intercompany transactions and balances are eliminated on consolidation.
Use of Estimates	Use of Estimates The preparation of Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of net sales and expenses during the reporting period. Actual results could differ from those estimates. The Company continually monitors and evaluates the estimates used as additional information becomes available. Adjustments will be made to these provisions periodically to reflect new facts and circumstances that may indicate that historical experience may not be indicative of current and/or future results.
Revenue Recognition	Revenue Recognition Net Sales The Company sells its products principally to a limited number of distributors, group purchasing organizations, eye care or health care professionals including independent practices, corporate retailers, hospitals and clinics or authorized resellers (collectively, its Customers). These Customers may subsequently resell the Company’s products to eye care or health care providers and patients. In addition to product supply and distribution agreements with Customers, the Company enters into arrangements with health care providers and payors that provide for government-mandated and/or privately negotiated rebates, chargebacks and discounts with respect to the purchase of the Company’s products. The Company considers purchase orders, which in some cases are governed by master sales agreements, to be contracts with a customer. As part of its consideration of the contract, the Company evaluates certain factors including the customer’s ability to pay (or credit risk). For each contract, the Company considers the promise to transfer products, each of which is distinct, to be the identified performance obligations. Revenues from product sales are recognized when the Customer obtains control of the Company’s product, which occurs at a point in time, typically upon shipment or delivery to the Customer. Taxes collected from Customers relating to product sales and remitted to governmental authorities are excluded from revenues. The Company expenses incremental costs of obtaining a contract as and when incurred if the expected amortization period of the asset that the Company would have recognized is one year or less. See Note 12. Business Segment Information for disaggregation of revenue. Reserves for Variable Consideration Revenues from product sales are recorded at the net sales price (transaction price), which includes estimates of variable consideration for which reserves are established and which result from discounts, returns, chargebacks, rebates and other allowances that are offered within contracts between the Company and its Customers, health care providers, payors and other indirect customers relating to the Company’s sales of its products. These reserves are based on the amounts earned or to be claimed on the related sales and are classified primarily in current liabilities. Variable consideration is estimated based on the most likely amount or expected value approach, depending on which method the Company expects to better predict the amount of consideration to which it will be entitled. Once the Company elects one of the methods to estimate variable consideration for a particular type of performance obligation, the Company applies that method consistently. Where appropriate, these estimates take into consideration a range of possible outcomes which are probability-weighted for relevant factors such as the Company’s historical experience, current contractual and statutory requirements, specific known market events and trends, industry data and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company’s best estimates of the amount of consideration to which it is entitled based on the terms of the contract. Trade Discounts and Allowances The Company generally provides Customers with discounts, which include incentive fees that are stated in the Company’s contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized. Product Returns Consistent with industry practice, the Company generally offers Customers a limited right of return for a product that has been purchased from the Company. The Company estimates the amount of its product sales that may be returned by its Customers and records this estimate as a reduction of revenue in the period the related product revenue is recognized. Historically, returns have been infrequent and insignificant relative to our total sales. Our refund liability for product returns is included in "Other current liabilities" in our Consolidated Balance Sheets and represents the expected value of the aggregate refunds that will be due to our customers. Rebates and Chargebacks Rebates are estimated based on contractual terms, historical experience, customer mix, trend analysis and projected market conditions in the various markets served. Chargebacks for fees and discounts to providers represent the estimated obligations resulting from contractual commitments to sell products to qualified healthcare providers at prices lower than the list wholesale prices charged to the Company’s direct customers. For certain office and surgical portfolio in CooperSurgical, customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue. Chargeback amounts are generally determined at the time of resale to the qualified healthcare provider by customers. CooperSurgical rebates are predominately related to the Medicaid rebate provision that is estimated based upon contractual terms, historical experience, and trend analysis. Contract Liabilities Deferred revenue primarily represents prepaid stem cell storage as part of the CooperSurgical business unit. Revenue related to stem cell storage is recognized over the service period, which can range from one year to the lifetime of a customer. The current portion of the deferred revenue balances at the beginning of each year presented were generally fully recognized in the subsequent 12-month period.
Share-Based Compensation	Share-Based Compensation We grant various share-based compensation awards, including stock options, performance unit shares, restricted stock and restricted stock units. The Company accounts for share-based compensation expense based on estimated grant-date fair value, and expenses the amount over the vesting period of the award. Determining the fair value of share-based awards at the grant date requires judgment, including estimating Cooper's stock price volatility, employee exercise behaviors and related employee forfeiture rates. The expected life of the share-based awards is based on the expected time to post-vesting forfeiture and/or exercise. Groups of employees that have similar historical exercise behavior are considered separately for valuation purposes. In determining the expected volatility, management considers implied volatility from publicly-traded options on Cooper's common stock at the date of grant, historical volatility and other factors. The risk-free interest rate is based on the continuous rates provided by the United States Treasury with a term equal to the expected life of the award. The dividend yield is based on the projected annual dividend payment per share, divided by the stock price at the date of grant. Forfeitures are estimated at the time of grant, based on historical experience, and revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates.
Foreign Currency Translation	Foreign Currency Translation Most of our operations outside the United States use their local currency as their functional currency. We translate these assets and liabilities into U.S. dollars at year-end exchange rates. We translate income and expense accounts at average exchange rates for the period. We record gains and losses from the translation of financial statements in foreign currencies into U.S. dollars in other comprehensive income. We record gains and losses from changes in exchange rates on transactions denominated in currencies other than each reporting location's functional currency in net income for each period
Financial Derivatives and Hedging	Financial Derivatives and Hedging Derivatives are recorded on the Consolidated Balance Sheets at fair value. Accounting for gains or losses resulting from changes in the values of those derivatives depends on the use of the derivative instrument and whether it qualifies for hedge accounting. The gain or loss on derivative instruments designated and qualifying for cash flow hedge accounting is deferred in other comprehensive income. The changes in fair value for all trades that are not designated for hedge accounting are recognized in current period earnings. Deferred gains or losses from designated cash flow hedges are reclassified into earnings in the period that the hedged interest expense affects earnings. The effectiveness of cash flow hedges is assessed at inception and quarterly thereafter. The Company does not offset fair value amounts recognized for derivative instruments in its Consolidated Balance Sheets for presentation purposes.
Fair Value Measurements	Fair Value Measurements The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value. An asset’s or liability’s level is based on the lowest level of input that is significant to the fair value measurement. Assets and liabilities carried at fair value are valued and disclosed in one of the following three levels of the valuation hierarchy: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions. The carrying value of cash and cash equivalents, accounts receivable, prepaid expense and other current assets, lines of credit, accounts payable and other current liabilities approximate fair value due to the short-term nature of such instruments and the ability to obtain financing on similar terms. The carrying value of the Company's revolving credit facility and term loans approximates fair value based on current market rates (Level 2). Refer to Note 5. Financing Arrangements for further information. The fair value of the Company's interest rate swap contracts is measured on a recurring basis by netting the discounted future fixed cash payments and the discounted expected variable cash receipts. The variable cash receipts are based on the expectation of future interest rates (forward curves) derived from observable market interest rate curves. The interest rate swap contracts were categorized as Level 2 in the fair value hierarchy, as the inputs to the derivative pricing model are generally observable and do not contain a high level of subjectivity. The fair value of derivative instruments is included in "Other assets" in our Consolidated Balance Sheets. On our Consolidated Financial Statements. the gain or loss on the derivatives is recorded as a component of "Accumulated other comprehensive loss" and subsequently reclassified into "Interest expense" in the same period during which the hedged transaction affects earnings. Refer to Note 13. Financial Derivatives and Hedging for further information. The Company uses fair value measures for assets and liabilities acquired in an acquisition, which are considered a Level 3 measurement. Contingent consideration for which a liability is recorded and the initial measurement of the joint venture interest are also categorized as Level 3 in the fair value hierarchy; and the change in fair value is recognized in "Selling, general and administrative expense" in the Consolidated Statements of Income. The fair value is measured by discounting expected future cash flows. The discount rate used for cash flows reflects capital market conditions and the specific risks associated with the business. Refer to Note 3. Acquisitions and Joint Venture for further information.
Income Taxes	Income Taxes Income taxes are estimated based on enacted income tax laws and the results of operations in each jurisdiction. Deferred tax assets and liabilities are estimated based on temporary differences between the financial reporting basis and income tax basis of assets and liabilities. Deferred tax assets are also estimated based on net operating loss and tax credit carryforwards. Deferred tax assets are reduced by a valuation allowance to the extent it is more likely than not they are not expected to be realized. Adjustments to deferred tax assets and liabilities due to changes in tax laws, changes in jurisdiction from intra-group transfers of assets, and changes in judgment regarding a valuation allowance are recognized in provision for income taxes in the quarter in which such changes occur. Long-term tax payable is estimated income tax to be paid for unrecognized tax benefits. A tax benefit is recognized if it is more likely than not a tax position will be sustained based on its technical merits in a tax authority examination, based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the tax authority. Adjustments to unrecognized tax benefits due to changes in judgment are recognized in provision for income taxes in the quarter in which such changes occur. Interest and penalties related to unrecognized tax benefits are recognized in provision for income taxes.
Earnings Per Share	Earnings Per Share We determine basic earnings per share (EPS) by using the weighted-average number of shares outstanding. We determine diluted EPS by increasing the weighted-average number of shares outstanding in the denominator by the number of outstanding dilutive equity awards using the treasury stock method.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term, highly liquid investments purchased with maturities of three months or less to be cash equivalents.
Inventories	Inventories Inventories are stated at the lower of cost or net realizable value. Cost is computed using standard cost that approximates actual cost, on a first-in, first-out basis. In assessing the value of inventories, we make estimates and judgments regarding aging of inventories and other relevant issues potentially affecting the salable condition of products and estimated prices at which those products will sell. On an ongoing basis, we review the carrying value of our inventory, measuring number of months on hand and other indications of salability. We reduce the value of inventory if there are indications that the carrying value is greater than net realizable value, resulting in a new, lower-cost basis for that inventory. Subsequent changes in facts and circumstances do not result in the restoration or increase in that newly established cost basis. While estimates are involved, historically, obsolescence has not been a significant factor due to long product dating and lengthy product life cycles.
Property, Plant and Equipment	Property, Plant and Equipment We record property, plant, and equipment at cost. We compute depreciation expense using the straight-line method over the estimated useful lives of the assets. Useful lives are generally 3 to 15 years except for buildings which are depreciated over 30 to 40 years and leasehold improvements, which we amortize over the shorter of the useful life or the lease term. We charge maintenance and repairs to expense as we incur them.
Leases	Leases We consider an arrangement a lease if the arrangement transfers the right to control the use of an identified asset in exchange for consideration. We have operating leases, but do not have material financing leases. The Company primarily has operating leases for office, manufacturing and warehouse space, vehicles, and office equipment. Lease right-of-use assets represent the right to use an underlying asset for the lease term, and lease liabilities represent the obligation to make payments arising from the lease agreement. These assets and liabilities are recognized at the commencement of the lease based upon the present value of the future lease payments over the lease term. The lease term reflects the noncancellable period of the lease together with periods covered by an option to extend or terminate the lease when management is reasonably certain that it will exercise such option. Changes in the lease term assumption could impact the right-of-use assets and lease liabilities recognized on the Consolidated Balance Sheets. As our leases typically do not contain a readily determinable implicit rate, we determine the present value of the lease liability using our incremental borrowing rate at the lease commencement date based on the lease term on a collateralized basis. The Company’s operating leases typically include non-lease components such as common-area maintenance costs. The Company has elected to include non-lease components with lease payments for the purpose of calculating lease right-of-use assets and liabilities, to the extent that they are fixed. Non-lease components that are not fixed are expensed as incurred as variable lease payments. Leases with a term of one year or less are not recognized in the Consolidated Balance Sheets, while the associated lease payments are expensed in the Consolidated Statements of Income and Comprehensive Income on a straight-line basis over the lease term. Operating leases are classified in “Other current liabilities”, “Other liabilities”, and “Other assets” in our Consolidated Balance Sheets. Operating lease expense is recognized on a straight-line basis over the expected lease term and included in "Selling, general and administrative expense" in our Consolidated Statements of Income. Financing leases are classified in "Property, plant and equipment, net", "Short-term debt", and "Long-term debt" in our Consolidated Balance Sheets.
Cloud Computing Arrangements	Cloud Computing Arrangements The Company capitalizes certain costs related to the acquisition and development of internal use software, including implementation costs incurred in a cloud computing arrangement, during the application development stages of projects. Capitalized implementation costs are amortized on a straight-line basis over the expected term of the hosting arrangement, which includes consideration of the non-cancellable contractual term and reasonably certain renewals. Costs incurred during the preliminary project or the post-implementation/operation stages of the project are expensed as incurred. Implementation costs are included in “Other assets” in our Consolidated Balance Sheets. Amortization of capitalized implementation costs is included in the same line item in the Consolidated Statements of Income as the expense for fees for the associated hosting arrangement.
Valuation of Goodwill	Valuation of Goodwill We evaluate goodwill for impairment annually during the fiscal third quarter and when an event occurs or circumstances change such that it is reasonably possible that impairment may exist. Goodwill is tested for impairment at the reporting unit level by performing a qualitative assessment to determine whether it is more likely than not that the fair value of the reporting unit is less than its carrying value. We perform a qualitative assessment to test each reporting unit's goodwill for impairment, which includes industry and market considerations, overall financial performance and other relevant events and factors affecting each reporting unit. Based on our qualitative assessment, if we determine that the fair value of a reporting unit is more likely than not to be less than its carrying amount, the fair value of a reporting unit will be compared with its carrying amount and an impairment charge will be recognized for the amount that the carrying value exceeds the fair value of the reporting unit.
Long-lived Assets	Long-lived Assets We review long-lived assets held and used for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset group may not be recoverable. If an evaluation of recoverability is required, the estimated undiscounted future cash flows associated with the asset group are compared to the asset group's carrying amount to determine if a write-down is required. If the undiscounted cash flows are less than the carrying amount, an impairment loss is recorded to the extent that the carrying amount exceeds the fair value.
Indefinite-lived Intangible Assets	Indefinite-lived Intangible Assets We assess indefinite-lived intangible assets annually in the third quarter of the fiscal year, or whenever events or changes in circumstances indicate that the carrying amount of an indefinite-lived intangible asset (asset group) may not be recoverable. We evaluate whether the indefinite-lived intangible asset is impaired by comparing its carrying value to its fair value. If the carrying value of an indefinite-lived intangible asset is not recoverable, an impairment loss is recognized based on the amount by which the carrying value exceeds the fair value.
Business Combinations	Business Combinations We routinely consummate business combinations. Results of operations for acquired companies are included in our consolidated results of operations from the date of acquisition. We recognize separately from goodwill, the identifiable assets acquired, including acquired in-process research and development, the liabilities assumed, and any noncontrolling interest in the acquiree at the acquisition date fair values as defined by accounting standards related to fair value measurements. Key assumptions routinely utilized in allocation of purchase price to intangible assets include discount rates and projected financial information such as revenue projections for companies acquired. As of the acquisition date, goodwill is measured as the excess of consideration given, over the net of the acquisition date fair values of the identifiable assets acquired and the liabilities assumed. Direct acquisition costs are expensed as incurred. For business acquisitions, the Company records tangible and intangible assets acquired and liabilities assumed at their fair values as of the applicable date of acquisition.
Litigation	Litigation We are subject to various legal proceedings, claims, litigation, investigations and contingencies arising out of the ordinary course of business. If we believe the likelihood of an adverse legal outcome is probable and the amount is estimable, we accrue a liability in accordance with accounting guidance for contingencies. We consult with legal counsel on matters related to litigation and seek input both within and outside the Company.
Treasury Stock	Treasury Stock We record treasury stock purchases under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock.
Government Assistance	Government Assistance The Company at times receives government assistance primarily to support manufacturing capital expansion, to create or retain jobs, or to provide tax credits mainly for eligible research and development activities. The Company generally accounts for such government assistance by analogy to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance and recognizes the assistance when it is probable that it will be received by complying with the prerequisite terms and conditions. The government assistance is recognized in income as a reduction to the cost basis of the applicable property, plant, and equipment or reduction to the related expense.
Accounting Pronouncements Recently Adopted and Accounting Pronouncements Issued Not Yet Adopted	Accounting Pronouncements Recently Adopted In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance. This update requires annual disclosures about transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. This standard was effective for fiscal years beginning after December 15, 2021. The Company adopted this guidance prospectively on November 1, 2022, and such adoption did not have a material impact on the Company's Consolidated Financial Statements. In March 2020, the FASB issued ASU 2020-04, Reference Rate Reform (Topic 848): Facilitation of the Effects of Reference Rate Reform on Financial Reporting and subsequent amendment to the initial guidance: ASU 2021-01, Reference Rate Reform (Topic 848): Scope (collectively, “Topic 848”). Topic 848 provides optional expedients and exceptions for applying GAAP to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments apply only to contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. In December 2022, the FASB issued ASU 2022-06, Reference Rate Reform (Topic 848): Deferral of the Sunset Date of Topic 848. ASU 2022-06 defers the sunset date of Topic 848 from December 31, 2022, to December 31, 2024. Effective February 1, 2023, the Company transitioned its credit agreements from LIBOR to the Secured Overnight Financing Rate ("SOFR"). The Company adopted this guidance prospectively on February 1, 2023, and it did not have a material impact on the Consolidated Financial Statements. Accounting Pronouncements Issued Not Yet Adopted No other recently issued accounting pronouncements had or are expected to have a material impact on our Consolidated Financial Statements.

Employee Benefits - Changes in Benefit Obligation, Changes in Plan Assets and Funded Status (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Change in benefit obligation
Benefit obligation, beginning of year	$ 148.0	$ 230.9	$ 218.8
Service cost	10.0	18.3	17.2
Interest cost	7.9	5.1	4.4
Benefits paid	(10.5)	(13.1)	(11.5)
Actuarial (gain)/loss	(10.9)	(93.2)	2.0
Benefit obligation, end of year	$ 144.5	$ 148.0	$ 230.9
Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Interest Cost, Statement of Income or Comprehensive Income [Extensible Enumeration]	Other liabilities	Other liabilities	Other liabilities
Change in plan assets
Fair value of plan assets, beginning of year	$ 142.9	$ 199.5	$ 159.5
Actual return on plan assets	4.1	(43.5)	38.8
Employer contributions	1.1	0.0	12.7
Benefits paid	(10.5)	(13.1)	(11.5)
Fair value of plan assets, end of year	137.6	142.9	199.5
Funded status at end of year	$ (6.9)	$ (5.1)	$ (31.4)

Business Segment Information (Tables)

12 Months Ended

Oct. 31, 2023

Segment Reporting [Abstract]

Schedule of business segment net sales

The following table presents a summary of our business segment net sales:


(In millions)	2023		2022		2021
CooperVision net sales by category:
Toric lens	$	828.7	$	737.4	$	697.5
Multifocal lens	305.7		264.4		238.6
Single-use sphere lens	705.4		661.6		616.3
Non single-use sphere, other	583.9		579.9		599.6
Total CooperVision net sales	2,423.7		2,243.3		2,152.0
CooperSurgical net sales by category:
Office and surgical	689.5		633.6		451.3
Fertility	480.0		431.5		319.2
Total CooperSurgical net sales	1,169.5		1,065.1		770.5
Total net sales	$	3,593.2	$	3,308.4	$	2,922.5

Schedule of business segment information

Information by business segment for each of the years in the three-year period ended October 31, 2023 follows:


(In millions)	CooperVision		CooperSurgical		Corporate		Consolidated
2023
Net sales	$	2,423.7	$	1,169.5	$	—	$	3,593.2
Operating income (loss)	$	587.7	$	16.1	$	(70.7)	$	533.1
Interest expense							105.3
Other expense, net							14.9
Income before income taxes							$	412.9
Identifiable assets	$	7,044.0	$	4,351.8	$	263.1	$	11,658.9
Depreciation expense	$	156.9	$	24.6	$	—	$	181.5
Amortization expense	$	32.9	$	153.3	$	—	$	186.2
Capital expenditures	$	364.4	$	28.1	$	—	$	392.5
2022
Net sales	$	2,243.3	$	1,065.1	$	—	$	3,308.4
Operating income (loss)	$	494.3	$	67.1	$	(53.8)	$	507.6
Interest expense							57.3
Other (income), net							(25.0)
Income before income taxes							$	475.3
Identifiable assets	$	6,778.9	$	4,407.8	$	305.6	$	11,492.3
Depreciation expense	$	144.5	$	22.1	$	—	$	166.6
Amortization expense	$	32.3	$	147.2	$	—	$	179.5
Capital expenditures	$	223.0	$	19.0	$	—	$	242.0
2021
Net sales	$	2,152.0	$	770.5	$	—	$	2,922.5
Operating income (loss)	$	481.3	$	71.8	$	(47.3)	$	505.8
Interest expense							23.1
Other expense, net							(8.8)
Income before income taxes							$	491.5
Identifiable assets	$	6,965.9	$	2,395.6	$	244.7	$	9,606.2
Depreciation expense	$	148.3	$	14.9	$	—	$	163.2
Amortization expense	$	35.7	$	110.4	$	—	$	146.1
Capital expenditures	$	190.0	$	24.4	$	—	$	214.4

Schedule of information by geographical area by country of domicile

Information by geographical area by country of domicile for each of the years in the three-year period ended October 31, 2023 follows:


(In millions)	United States		Europe		Rest of World, Other Eliminations & Corporate		Consolidated
2023
Net sales to unaffiliated customers	$	1,812.2	$	1,041.2	$	739.8	$	3,593.2
Sales between geographic areas	563.1		1,016.7		(1,579.8)		—
Net sales	$	2,375.3	$	2,057.9	$	(840.0)	$	3,593.2
Operating income	$	—	$	516.2	$	16.9	$	533.1
Long-lived assets	$	1,027.6	$	325.9	$	279.1	$	1,632.6
2022
Net sales to unaffiliated customers	$	1,638.5	$	987.2	$	682.7	$	3,308.4
Sales between geographic areas	514.4		897.3		(1,411.7)		—
Net sales	$	2,152.9	$	1,884.5	$	(729.0)	$	3,308.4
Operating (loss) income	$	71.8	$	403.8	$	32.0	$	507.6
Long-lived assets	$	856.1	$	310.8	$	266.0	$	1,432.9
2021
Net sales to unaffiliated customers	$	1,339.2	$	957.9	$	625.4	$	2,922.5
Sales between geographic areas	494.9		815.1		(1,310.0)		—
Net sales	$	1,834.1	$	1,773.0	$	(684.6)	$	2,922.5
Operating (loss) income	$	(26.8)	$	416.2	$	116.4	$	505.8
Long-lived assets	$	737.5	$	377.2	$	232.9	$	1,347.6

Contingencies	12 Months Ended
Contingencies	Oct. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Contingencies	Note 11. Contingencies The Company is involved in various lawsuits, claims and other legal matters from time to time that arise in the ordinary course of conducting business, including matters involving our products, intellectual property, supplier relationships, distributors, competitor relationships, employees and other matters. The Company does not believe that the ultimate resolution of these proceedings or claims pending against it could have a material adverse effect on its financial condition or results of operations. At each reporting period, the Company evaluates whether or not a potential loss amount or a potential range of loss is probable and reasonably estimable under ASC 450, Contingencies. Legal fees are expensed as incurred.

Business Segment Information - Narrative (Details)	12 Months Ended
Business Segment Information - Narrative (Details)	Oct. 31, 2023 segment
Segment Reporting [Abstract]
Number of operating segments	2

Acquisitions and Joint Venture (Details)					1 Months Ended	12 Months Ended
Acquisitions and Joint Venture (Details)	Nov. 01, 2023 USD ($) installment	Nov. 01, 2022 USD ($)	Apr. 06, 2022 USD ($)	Dec. 17, 2021 USD ($)	Mar. 31, 2022 USD ($)	Oct. 31, 2023 USD ($)	Oct. 31, 2022 USD ($)	Oct. 31, 2021 USD ($)	Jan. 19, 2021 USD ($)
Business Acquisition [Line Items]
Goodwill						$ 3,624,500,000	$ 3,609,700,000
Proceeds from sale of interest in a subsidiary					$ 52,100,000	0	52,100,000	$ 0
Payments to form joint venture					10,000,000
Equity method investments					90,000,000
Equity method investment realized gain							56,900,000
Decrease in contingent consideration liability						31,800,000	10,300,000	$ (66,100,000)
Essilor International SAS
Business Acquisition [Line Items]
Payments to form joint venture					$ 10,000,000
SightGlass Vision, Inc.
Business Acquisition [Line Items]
Equity method investment, ownership percentage					50.00%
Privately-Held U.S.-Based Company, Technologically Advanced Contact Lens Products
Business Acquisition [Line Items]
Aggregate consideration		$ 33,000,000
Net assets		5,100,000
Goodwill		7,700,000
Goodwill, expected tax deductible amount		0
Privately-Held U.S.-Based Company, Technologically Advanced Contact Lens Products \| Customer relationships
Business Acquisition [Line Items]
Finite-lived intangibles		12,600,000
Privately-Held U.S.-Based Company, Technologically Advanced Contact Lens Products \| Technology
Business Acquisition [Line Items]
Finite-lived intangibles		$ 7,600,000
Cook Medicals Reproductive Health Business
Business Acquisition [Line Items]
Aggregate consideration			$ 875,000,000
Payments to acquire business			675,000,000
Payables incurred in acquisition			200,000,000
Acquisition termination fee						45,000,000
Cook Medicals Reproductive Health Business \| Payables First Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			50,000,000
Cook Medicals Reproductive Health Business \| Payables Second Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			50,000,000
Cook Medicals Reproductive Health Business \| Payables Third Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			50,000,000
Cook Medicals Reproductive Health Business \| Payables Fourth Installment
Business Acquisition [Line Items]
Payables incurred in acquisition			$ 50,000,000
Generate Life Sciences
Business Acquisition [Line Items]
Payments to acquire business				$ 1,663,000,000
Ownership percentage				100.00%
Generate Life Sciences \| Line of Credit \| Term Loan Facility 2021
Business Acquisition [Line Items]
Proceeds from line of credit				$ 1,500,000,000
Privately-Held Medical Device Company, Spectacle Lenses, Portion Attributable To Former Equity Interest Owners
Business Acquisition [Line Items]
Undiscounted range of the contingent consideration, minimum									$ 0
Undiscounted range of the contingent consideration, maximum									$ 139,100,000
Payment to settle former equity interest owners					$ 42,900,000
Equity investment gain realized before acquisition of remaining equity interest							$ 12,200,000
Decrease in contingent consideration liability						$ 31,800,000
Cook Medical \| Subsequent Event
Business Acquisition [Line Items]
Aggregate consideration	$ 300,000,000
Payments to acquire business	200,000,000
Payables incurred in acquisition	$ 100,000,000
Number of installments \| installment	2
Cook Medical \| Payables First Installment \| Subsequent Event
Business Acquisition [Line Items]
Payables incurred in acquisition	$ 50,000,000
Cook Medical \| Payables Second Installment \| Subsequent Event
Business Acquisition [Line Items]
Payables incurred in acquisition	$ 50,000,000

Organization and Significant Accounting Policies (Tables)

12 Months Ended

Oct. 31, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of inventory


October 31, (In millions)	2023		2022
Raw materials	$	207.3	$	173.7
Work-in-process	19.0		15.2
Finished goods	509.3		439.8
	$	735.6	$	628.7

Schedule of property, plant and equipment


October 31, (In millions)	2023		2022
Land and improvements	$	20.2	$	18.7
Buildings and improvements	488.5		415.6
Machinery and equipment	2,187.1		1,973.6
Construction in progress	486.3		393.0
Property, plant and equipment, at cost	$	3,182.1	$	2,800.9
Less: Accumulated depreciation	1,553.3		1,387.2
Property, plant and equipment, net	$	1,628.8	$	1,413.7
Finance lease ROU assets, net	3.8		19.2
	$	1,632.6	$	1,432.9

Employee Benefits - Reconciliation of Prepaid (Accrued) Pension Cost (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$ (2.9)	$ (13.0)	$ (14.8)
Net periodic benefit cost	6.8	10.1	14.5
Contributions made during the year	(1.1)	0.0	(12.7)
(Prepaid)/Accrued pension cost at fiscal year end	$ 2.8	$ (2.9)	$ (13.0)

Financing Arrangements

12 Months Ended

Oct. 31, 2023

Debt Disclosure [Abstract]

Financing Arrangements

Note 5. Financing Arrangements

The Company had outstanding debt as follows:


October 31, (In millions)	2023		2022
Overdraft and other credit facilities	$	44.4	$	57.7
Term loans	—		338.0

Short-term debt, excluding financing leases	44.4		395.7
Financing lease liabilities	1.0		16.9
Short-term debt	$	45.4	$	412.6

Revolving credit	$	172.6	$	—
Term loans	2,350.0		2,350.0
Other	0.2		0.2
Less: unamortized debt issuance cost	(2.4)		(3.1)
Long-term debt, excluding financing leases	2,520.4		2,347.1

Financing lease liabilities	3.4		3.7
Long-term debt	$	2,523.8	$	2,350.8
Total debt	$	2,569.2	$	2,763.4

As of October 31, 2023, the Company was in compliance with all debt covenants. On February 1, 2023, the Company amended its credit agreements to transition the interest rates applicable to the loans denominated in U.S. dollars from LIBOR to SOFR, as defined in the credit agreements.

Term Loan Agreement on December 17, 2021

On December 17, 2021, the Company entered into a Term Loan Agreement (the 2021 Credit Agreement) by and among the Company, the lenders from time to time party thereto, and PNC Bank, National Association, as administrative agent. The 2021 Credit Agreement provides for a term loan facility (the 2021 Term Loan Facility) in an aggregate principal amount of $1.5 billion, which, unless terminated earlier, matures on December 17, 2026. In addition, the Company has the ability from time to time to request an increase to the commitments under the 2021 Term Loan Facility or to establish a new term loan facility under the 2021 Credit Agreement in an aggregate principal amount not to exceed $1.125 billion, upon prior written

notice to the administrative agent and subject to the discretionary participation of the lenders funding such term loans and certain limitations set forth in the 2021 Credit Agreement.

Amounts outstanding under the 2021 Term Loan Facility will bear interest, at the Company’s option, at either (i) the alternate base rate, which is a rate per annum equal to the greatest of (a) the administrative agent’s prime rate, (b) one-half of one percent in excess of the federal funds effective rate and (c) one percent in excess of the adjusted SOFR for a one-month interest period in effect on such day, or (ii) the adjusted SOFR, plus, in each case, an applicable rate of, initially, zero basis points, in respect of base rate loans, and 75 basis points, in respect of adjusted SOFR loans. Following a specified period after the closing date, the applicable rates will be determined quarterly by reference to a grid based upon the Company’s ratio of consolidated net indebtedness to consolidated EBITDA, each as defined in the 2021 Credit Agreement.

The Company may prepay loan balances from time to time, in whole or in part, without premium or penalty (other than any related breakage costs).

On October 31, 2023, the Company had $1.5 billion outstanding on the 2021 Term Loan Facility and the weighted-average interest rate was 6.41%.

The 2021 Credit Agreement contains customary restrictive covenants, as well as financial covenants that require the Company to maintain a certain Total Leverage Ratio and Interest Coverage Ratio, each as defined in the 2021 Credit Agreement, consistent with the 2020 Credit Agreement discussed below.

Term Loan Agreement on November 2, 2021

On November 2, 2021, the Company entered into a 364-day, $840.0 million, term loan agreement by and among the Company, the lenders party thereto and The Bank of Nova Scotia, as administrative agent, which matured subsequent to year end on November 1, 2022. The Company used part of the funds to partially repay outstanding borrowings under the 2020 Revolving Credit Facility and for general corporate purposes. The loan was fully repaid by the maturity date.

Revolving Credit and Term Loan Agreement on April 1, 2020

On April 1, 2020, the Company entered into a Revolving Credit and Term Loan Agreement (the 2020 Credit Agreement), among the Company, CooperVision International Holding Company, LP, CooperSurgical Netherlands B.V., CooperVision Holding Kft. the lenders from time to time party thereto, and KeyBank National Association, as administrative agent. The 2020 Credit Agreement provides for (a) a multicurrency revolving credit facility (the 2020 Revolving Credit Facility) in an aggregate principal amount of $1.29 billion and (b) a term loan facility (the 2020 Term Loan Facility) in an aggregate principal amount of $850.0 million, each of which, unless terminated earlier, mature on April 1, 2025. The Company used $850.0 million under the 2020 Term Loan Facility and $445.0 million under the 2020 Revolving Credit Facility to fully repay all borrowings outstanding under a previously existing term loan agreement and transfer all letters of credit and borrowings outstanding under a previously existing credit agreement to the 2020 Credit Agreement. The Company has an uncommitted option to increase the revolving credit facility or establish a new term loan in an aggregate amount up to $1.605 billion.

On October 30, 2020, the Company entered into Amendment No. 1 to the 2020 Credit Agreement, adding CooperVision International Limited as a revolving borrower and releasing certain borrowers in the 2020 Credit Agreement.

On December 17, 2021, the Company entered into Amendment No.2 to the 2020 Credit Agreement, modifying the 2020 Credit Agreement by, among other things, adding CooperSurgical Holdings Limited as a revolving borrower, releasing CooperVision Holding Kft as a borrower, and updating the benchmark replacement language in the 2020 Credit Agreement.

The 2020 Credit Agreement will bear interest, at the Company’s option, at either the alternate base rate, or the adjusted SOFR, or adjusted foreign currency rate, plus, in each case, an applicable rate of between 0.00% and 0.50% in respect of base rate loans, and between 0.75% and 1.50% in respect of adjusted SOFR or adjusted foreign currency rate loans, in each case in accordance with a pricing grid tied to the Total Leverage Ratio, as defined in the 2020 Credit Agreement. The Company may borrow, repay and re-borrow amounts available under the Revolving Credit Facility, subject to voluntary reduction of the revolving commitment.

The Company pays an annual commitment fee that ranges from 0.10% to 0.20% of the unused portion of the 2020 Revolving Credit Facility based upon the Company’s Total Leverage Ratio, as defined in the 2020 Credit Agreement.

On October 31, 2023, the Company had $850.0 million outstanding under the 2020 Term Loan Facility and $172.6 million outstanding under the 2020 Revolving Credit Facility. The interest rate on the 2020 Term Loan Facility was 6.41% at October 31, 2023. The weighted-average interest rate on the 2020 Revolving Credit Facility was 6.41% at October 31, 2023.

Payments on the outstanding long-term debt balance of $850.0 million are due in the fiscal year ending October 31, 2025.

European and Asian Pacific Credit Facilities

The Company maintains European credit facilities. The aggregate facility limit was $32.9 million and $30.7 million at October 31, 2023 and 2022, respectively. At October 31, 2023, $0.7 million of the facilities was utilized and the weighted-average interest rate on the outstanding balances was 7.82%.

The Company maintains yen-denominated credit facilities in Japan. The aggregate facility limit was $74.3 million and $73.0 million at October 31, 2023 and 2022, respectively. At October 31, 2023, $41.4 million of the combined facilities was utilized and the weighted-average interest rate on the outstanding balances was 0.40%.

Each facility is supported by a continuing and unconditional guaranty.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

Employee Benefits

12 Months Ended

Oct. 31, 2023

Retirement Benefits [Abstract]

Employee Benefits

Note 10. Employee Benefits

Cooper's Retirement Income Plan

The Company's Retirement Income Plan (Plan), a defined benefit plan, is only available to full-time United States employees, subject to the soft freeze mentioned below. The Company's contributions are designed to fund normal cost on a current basis and to fund the estimated prior service cost of benefit improvements. The unit credit actuarial cost method is used to determine the annual cost. The Company pays the entire cost of the Plan and funds such costs as they accrue. Virtually all of the assets of the Plan are comprised of equities and participation in equity and fixed income funds.

The Company uses individual spot rates along the yield curve that correspond with the timing of each benefit payment to determine the service and interest costs of components of its net periodic benefit cost utilizing the correlation of projected cash outflows and corresponding spot rates on the yield curve.

Retirement Income Plan


Years Ended October 31, (In millions)	2023		2022		2021
Change in benefit obligation
Benefit obligation, beginning of year	$	148.0	$	230.9	$	218.8
Service cost	10.0		18.3		17.2
Interest cost	7.9		5.1		4.4
Benefits paid	(10.5)		(13.1)		(11.5)

Actuarial (gain)/loss	(10.9)		(93.2)		2.0
Benefit obligation, end of year	$	144.5	$	148.0	$	230.9
Change in plan assets
Fair value of plan assets, beginning of year	$	142.9	$	199.5	$	159.5
Actual return on plan assets	4.1		(43.5)		38.8
Employer contributions	1.1		—		12.7
Benefits paid	(10.5)		(13.1)		(11.5)
Fair value of plan assets, end of year	$	137.6	$	142.9	$	199.5
Funded status at end of year	$	(6.9)	$	(5.1)	$	(31.4)


Years Ended October 31, (In millions)	2023		2022		2021
Amounts recognized in accumulated other comprehensive income consist of:


Net loss	$	4.1	$	8.0	$	44.4
Accumulated other comprehensive income	$	4.1	$	8.0	$	44.4


Years Ended October 31, (In millions)	2023		2022		2021
Reconciliation of (prepaid) accrued pension cost:
(Prepaid)/Accrued pension cost at prior fiscal year end	$	(2.9)	$	(13.0)	$	(14.8)
Net periodic benefit cost	6.8		10.1		14.5
Contributions made during the year	(1.1)		—		(12.7)

(Prepaid)/Accrued pension cost at fiscal year end	$	2.8	$	(2.9)	$	(13.0)


Years Ended October 31, (In millions)	2023		2022		2021
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Net periodic benefit cost:
Service cost	$	10.0	$	18.3	$	17.2
Interest cost	7.9		5.1		4.4
Expected return on plan assets	(11.1)		(15.5)		(12.5)


Recognized actuarial loss	—		2.2		5.4
Net periodic pension cost	$	6.8	$	10.1	$	14.5


Years Ended October 31, (In millions)	2023		2022		2021
Other changes in plan assets and benefit obligations recognized in other comprehensive income:


Net (gain) loss	$	(4.0)	$	(34.1)	$	(24.4)


Amortizations of net gain	—		(2.5)		(5.4)



Total recognized in other comprehensive (income) loss	$	(4.0)	$	(36.6)	$	(29.8)
Total recognized in net periodic benefit cost and other comprehensive (income) loss	$	2.8	$	(26.2)	$	(15.2)


Years Ended October 31,	2023		2022		2021
Weighted-average assumptions used in computing the net periodic pension cost and projected benefit obligation at year end:
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	5.74	%	2.76	%	2.78	%
Service Cost	5.77	%	2.79	%	2.86	%
Interest Cost	5.51	%	2.28	%	2.07	%
Discount rate for determining benefit obligations at year end	6.22	%	5.74	%	2.76	%
Rate of compensation increase for determining expense	3.60	%	3.60	%	3.60	%
Rate of compensation increase for determining benefit obligations at year end	3.60	%	3.60	%	3.60	%
Expected rate of return on plan assets for determining net periodic pension cost	8.00	%	8.00	%	8.00	%
Expected rate of return on plan assets at year end	8.00	%	8.00	%	8.00	%
Measurement date for determining assets and benefit obligations at year end	10/31/2023		10/31/2022		10/31/2021

The discount rate enables us to state expected future cash flows at a present value on the measurement date. The discount rate used for the Plan is based primarily on the yields of a universe of high-quality corporate bonds rated AA or above, with durations corresponding to the expected durations of the benefit obligations. A change in the discount rate will cause the present value of benefit obligations to change in the opposite direction.

The expected rate of return on plan assets was determined based on a review of historical returns, both for this plan and for medium- to large-sized defined benefit pension funds with similar asset allocations. This review generated separate expected returns for each asset class listed below. These expected future returns were then blended based on this Plan's target asset allocation.

Reasons for Significant Liability Gains and Losses

The projected benefit obligation experienced a net gain of approximately $10.9 million during the year. This net gain is the result of assumption changes resulting in a gain of approximately $12.9 million, offset by losses of approximately $2.0 million due to demographic experience. The key assumption changes were the increase in the discount rate (gain of $7.8 million), a changes in assumptions for lump sum determination (gain of $5.1 million). Demographic losses were due to the net effect of retirement rates, termination rates, salary increases and other experience that was different from assumed.

Plan Assets

Weighted-average asset allocations at year end, by asset category are as follows:


Years Ended October 31,	2023		2022		2021
Asset category
Cash and cash equivalents	2.9	%	2.0	%	5.0	%
Corporate common stock	26.0	%	33.6	%	31.6	%
Equity mutual funds	39.1	%	33.9	%	32.8	%
Balanced funds	2.4	%	1.8	%	1.4	%
Alternative investments	0.7	%	0.9	%	1.0	%


Bond mutual funds	28.9	%	27.8	%	28.2	%
Total	100.0	%	100.0	%	100.0	%

The Plan invests in a diversified portfolio of assets intended to minimize risk of poor returns while maximizing expected portfolio returns. To achieve the long-term rate of return, plan assets will be invested in a mixture of instruments, including but not limited to, corporate common stock (may include the Company's stock), investment grade bond funds, cash, balanced funds, real estate funds, small or large cap equity funds and international equity funds. The allocation of assets will be determined by the investment manager and will typically include 50% to 70% equities with the remainder invested in fixed income, hedging strategy funds and cash. Presently, this diversified portfolio is expected to return roughly 8% in the long run.

As of the measurement date of October 31, 2023, the fair value measurement of plan assets is as follows:


(In millions)	Total		Quoted Prices in Active Markets for Identical Assets (Level 1)		Significant Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Asset category
Cash and cash equivalents	$	3.9	$	3.9	$	—	$	—
Corporate common stock	35.8		35.8		—		—
Equity mutual funds	53.9		53.9		—		—
Balanced Funds	3.3		3.3		—		—
Alternative investments	0.9		0.9		—		—
Fixed income	39.8		15.8		24.0		—


Total	$	137.6	$	113.6	$	24.0	$	—

The Plan has an established process for determining the fair value of plan assets. For investments in equity and bond mutual funds, and real estate funds, fair value is based on observable, Level 1 inputs.

Plan Cash Flows

Contributions

The Company made $1.1 million and no contributions to the Plan in fiscal 2023 and fiscal 2022, respectively. The Company contribution to the Plan was $12.7 million for fiscal 2021. The Company closely monitors the funded status of the Plan with respect to legislative and accounting rules. The Company expected to make contributions totaling $1.1 million to the Plan during fiscal 2024.

Estimated Future Benefit Payments


Years (In millions)
2024	$	10.9
2025	$	11.0
2026	$	10.3
2027	$	11.2
2028	$	12.3
2029-2033	$	65.9

Plan Soft Freeze

On June 18, 2019, the Board of Directors of the Company approved a soft freeze of the Plan effective August 1, 2019. The Plan was closed to employees hired on or after August 1, 2019, including former participants or employees rehired on or after August 1, 2019, and employees hired in connection with a stock or asset acquisition, merger or other similar transaction on or after August 1, 2019. Existing employees already covered by the Plan, continue to accrue their benefits.

Cooper's 401(k) Savings Plan

Cooper's 401(k) savings plan provides for the deferral of compensation as described in the Internal Revenue Code and is available to substantially all United States employees. Employees who participate in the 401(k) plan may elect to have up to 75% of their pre-tax salary or wages deferred and contributed to the trust established under the Plan. Cooper's contributions on account of participating employees, were $10.1 million, $9.0 million and $7.2 million for the years ended October 31, 2023, 2022 and 2021, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480266/715-60-50-3

+ Details

Stock Plans - Narrative (Details) $ / shares in Units, $ in Millions			1 Months Ended	12 Months Ended
	Mar. 31, 2023 director shares	Mar. 18, 2019 shares	Mar. 31, 2016 director shares	Oct. 31, 2023 USD ($) $ / shares shares	Oct. 31, 2022 USD ($) $ / shares shares	Oct. 31, 2021 USD ($) $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost related to nonvested options				$ 17.6
Share-based compensation expense				$ 62.1	$ 54.2	$ 44.7
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period				2 years 1 month 6 days
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period				2 years 4 months 24 days
Total unrecognized compensation cost related to nonvested units				$ 63.1
Fair value of vested grants				$ 37.3	46.1	50.1
Performance Units
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Total unrecognized compensation cost expected to be recognized over a remaining weighted-average vesting period				1 year 8 months 12 days
Total unrecognized compensation cost related to nonvested units				$ 12.3
Performance Units \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target percentage of shares earned				0.00%
Performance Units \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Target percentage of shares earned				200.00%
Third Amended and Restated 2007 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of non-employee directors in committee \| director			2
Number of shares authorized to be granted \| shares			6,930,000
2023 Long-Term Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of non-employee directors in committee \| director	2
Number of shares authorized to be granted \| shares	1,365,000
Shares remaining for future grant (in shares) \| shares				1,376,240
Third Amended And Restated 2007 Long-Term Incentive Plan And 2023 Long-Term Incentive Plan \| Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total intrinsic value of options exercised				$ 13.4	$ 6.6	$ 64.7
Weighted-average fair value of each option granted (in dollars per share) \| $ / shares				$ 103.17	$ 90.41	$ 84.10
Award expiration date (no more than)				10 years
Third Amended And Restated 2007 Long-Term Incentive Plan And 2023 Long-Term Incentive Plan \| Stock Options \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Third Amended And Restated 2007 Long-Term Incentive Plan And 2023 Long-Term Incentive Plan \| Stock Options \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				5 years
Third Amended And Restated 2007 Long-Term Incentive Plan And 2023 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				3 years
Third Amended And Restated 2007 Long-Term Incentive Plan And 2023 Long-Term Incentive Plan \| Restricted Stock Units (RSUs) \| Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award vesting period				5 years
Employee Stock Purchase Plan \| Employee Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized to be granted \| shares		1,000,000
Exercise price percentage of fair market value on date of grant of awards		85.00%
Number of shares issued to employees \| shares				26,116	22,695
Number of shares remaining available for future issuance \| shares				921,975
Share-based compensation expense				$ 1.3	$ 1.1

Intangible Assets - Narrative (Details)	12 Months Ended
Intangible Assets - Narrative (Details)	Oct. 31, 2023 USD ($) reporting_unit	Oct. 31, 2022 USD ($)	Oct. 31, 2021 USD ($)
Goodwill [Line Items]
Number of reporting units \| reporting_unit	3
Goodwill impairment	$ 0	$ 0	$ 0
Impairment of definite-lived intangible assets	0	0	0
Impairment of indefinite-lived intangible assets	0	0	$ 0
CooperSurgical
Goodwill [Line Items]
Goodwill deductible for tax purposes	237,600,000	214,100,000
CooperVision
Goodwill [Line Items]
Goodwill deductible for tax purposes	$ 20,100,000	$ 22,400,000

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

Consolidated Statements of Cash Flows - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Cash flows from operating activities:
Net income	$ 294.2	$ 385.8	$ 2,944.7
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	367.7	346.1	309.3
Share-based compensation expense	62.1	54.2	43.8
Non-cash operating lease expense	40.0	32.2	31.8
Asset impairment charges, and other	49.4	4.5	(5.0)
Change in fair value of contingent consideration	(31.8)	(10.3)	66.1
Deferred income taxes	44.7	53.9	(2,502.2)
Change in assets and liabilities:
Accounts receivable	(60.2)	(33.8)	(75.5)
Inventories	(105.4)	(40.4)	(9.2)
Other assets	(89.4)	(16.9)	(69.1)
Operating lease right-of-use assets and liabilities, net	(34.2)	(51.3)	(27.5)
Accounts payable	5.5	49.9	(16.0)
Accrued liabilities	71.8	32.4	59.1
Accrued income taxes	(0.5)	(27.4)	10.0
Other long-term liabilities	(6.4)	(34.2)	(21.7)
Settlement of contingent consideration	0.0	(52.3)	0.0
Net cash provided by operating activities	607.5	692.4	738.6
Cash flows from investing activities:
Purchases of property, plant and equipment	(392.5)	(242.0)	(214.4)
Acquisitions of businesses and assets, net of cash acquired	(56.5)	(1,641.3)	(235.9)
Proceeds from sale of interest in a subsidiary	0.0	52.1	0.0
Net cash used in investing activities	(449.0)	(1,831.2)	(450.3)
Cash flows from financing activities:
Proceeds from long-term debt, net of issuance costs	2,124.2	1,511.0	1,427.4
Repayments of long-term debt	(1,953.9)	(561.5)	(1,416.0)
Net proceeds from (repayments of) short-term debt, other	(351.1)	329.3	(321.3)
Repurchase of common stock	0.0	(78.5)	(24.8)
Proceeds related to share-based compensation awards	15.1	8.9	33.7
Payments related to share-based compensation awards	(13.1)	(16.8)	(13.2)
Dividends on common stock	(3.0)	(3.0)	(3.0)
Issuance of common stock for employee stock purchase plan	7.9	7.2	5.8
Settlement of contingent consideration	0.0	(2.9)	0.0
Net cash (used in) provided by financing activities	(173.9)	1,193.7	(311.4)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	(2.3)	(12.9)	2.9
Net (decrease) increase in cash, cash equivalents and restricted cash	(17.7)	42.0	(20.2)
Cash, cash equivalents, restricted cash and cash held for sale at beginning of year	138.6	96.6	116.8
Cash, cash equivalents and restricted cash at end of year	120.9	138.6	96.6
Supplemental disclosures of cash flow information:
Interest	117.5	49.1	28.4
Income taxes	67.8	66.6	63.2
Operating lease liabilities	47.5	45.3	37.4
Operating lease ROU assets obtained in exchange for lease obligations	42.6	29.8	26.5
Reconciliation of cash flow information:
Cash and cash equivalents	120.8	138.2	95.9
Restricted cash included in other current assets	0.1	0.4	0.4
Cash held for sale	0.0	0.0	0.3
Total cash, cash equivalents, restricted cash and cash held for sale	$ 120.9	$ 138.6	$ 96.6

Organization and Significant Accounting Policies - Inventory (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 207.3	$ 173.7
Work-in-process	19.0	15.2
Finished goods	509.3	439.8
Inventories, net	$ 735.6	$ 628.7

Income Taxes - Changes in Unrecognized Tax Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022
Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]
Beginning of the period	$ 336.9	$ 353.8
Decrease based on tax positions in prior fiscal years	(0.5)	(12.5)
Settlements		(0.2)
Lapses of statutes of limitations	(6.9)	(4.2)
Increase based on tax positions in current fiscal year	2.0
End of the period	$ 331.5	$ 336.9

Cover Page - USD ($)
$ in Billions

12 Months Ended

Oct. 31, 2023

Dec. 01, 2023

Apr. 28, 2023

Cover [Abstract]

Document Type

10-K

Document Annual Report

true

Document Period End Date

Oct. 31, 2023

Current Fiscal Year End Date

--10-31

Document Transition Report

false

Entity File Number

001-08597

Entity Registrant Name

THE COOPER COMPANIES, INC.

Entity Incorporation, State or Country Code

Entity Tax Identification Number

94-2657368

Entity Address, Address Line One

6101 Bollinger Canyon Road

Entity Address, Address Line Two

Suite 500

Entity Address, City or Town

San Ramon

Entity Address, State or Province

Entity Address, Postal Zip Code

94583

City Area Code

925

Local Phone Number

460-3600

Title of 12(b) Security

Common Stock, $.10 par value

Trading Symbol

COO

Security Exchange Name

NASDAQ

Entity Well-Known Seasoned Issuer

Yes

Entity Voluntary Filers

Entity Current Reporting Status

Yes

Entity Interactive Data Current

Yes

Entity Filer Category

Large Accelerated Filer

Entity Small Business

false

Entity Emerging Growth Company

false

ICFR Auditor Attestation Flag

true

Documents Incorporated by Reference


Document						Part of Form 10-K
Portions of the Proxy Statement for the Annual Meeting of Stockholders scheduled to be held in March 2024						Part III

Our independent registered public accounting firm is KPMG LLP, San Francisco, CA, Auditor ID: 185.

Entity Shell Company

false

Entity Public Float

$ 18.8

Entity Common Stock, Shares Outstanding

49,525,982

Amendment Flag

false

Document Fiscal Year Focus

2023

Document Fiscal Period Focus

Entity Central Index Key

0000711404

Document Financial Statement Error Correction [Flag]

false

Employee Benefits - Amounts Recognized in Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Amounts recognized in accumulated other comprehensive income consist of:
Net loss	$ 4.1	$ 8.0	$ 44.4
Accumulated other comprehensive income	$ 4.1	$ 8.0	$ 44.4

Financing Arrangements (Tables)

12 Months Ended

Oct. 31, 2023

Debt Disclosure [Abstract]

Schedule of debt

The Company had outstanding debt as follows:


October 31, (In millions)	2023		2022
Overdraft and other credit facilities	$	44.4	$	57.7
Term loans	—		338.0

Short-term debt, excluding financing leases	44.4		395.7
Financing lease liabilities	1.0		16.9
Short-term debt	$	45.4	$	412.6

Revolving credit	$	172.6	$	—
Term loans	2,350.0		2,350.0
Other	0.2		0.2
Less: unamortized debt issuance cost	(2.4)		(3.1)
Long-term debt, excluding financing leases	2,520.4		2,347.1

Financing lease liabilities	3.4		3.7
Long-term debt	$	2,523.8	$	2,350.8
Total debt	$	2,569.2	$	2,763.4

Financial Derivatives and Hedging - Narrative (Details) $ in Millions	12 Months Ended
	Oct. 31, 2023 USD ($) interest_rate_swap_contract
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative loss expected to be realized in earnings over the next twelve months	$ (48.2)
Foreign Exchange Forward
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount	56.2
Interest Rate Swap
Derivative Instruments and Hedging Activities Disclosures [Line Items]
Derivative notional amount	$ 1,300.0
Number of interest rate swap contracts held \| interest_rate_swap_contract	6
Derivative, term of contract (or less)	4 years

Organization and Significant Accounting Policies - Property Plant and Equipment (Details) - USD ($) $ in Millions	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 3,182.1	$ 2,800.9
Less: Accumulated depreciation	1,553.3	1,387.2
Property, plant and equipment, net	1,628.8	1,413.7
Finance lease ROU assets, net	3.8	19.2
Property, plant and equipment, net	1,632.6	1,432.9	$ 1,347.6
Land and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	20.2	18.7
Buildings and improvements
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	488.5	415.6
Machinery and equipment
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	2,187.1	1,973.6
Construction in progress
Property, Plant and Equipment [Line Items]
Property, plant and equipment, at cost	$ 486.3	$ 393.0

Stock Plans

12 Months Ended

Oct. 31, 2023

Share-Based Payment Arrangement [Abstract]

Stock Plans

Note 9. Stock Plans

2007 Long-Term Incentive Plan (2007 Plan)

In March 2007, we received stockholder approval of the 2007 Plan. The 2007 Plan was subsequently amended and restated, and granted stockholder approval in March 2009, March 2011, and March 2016.

The Third Amended and Restated 2007 Plan authorizes either our Board of Directors, or a designated committee thereof composed of two or more Non-Employee Directors, to grant to eligible individuals during the period ending December 31, 2026, up to 6,930,000 shares in the form of specified equity awards including stock options, restricted stock units and performance share awards. RSUs have no dividend or voting rights prior to vesting. Awards under the 2007 Plan remain outstanding but new awards are no longer being granted.

2023 Long-Term Incentive Plan (2023 Plan)

In March 2023, we received stockholder approval of the 2023 Plan. The 2023 Plan authorizes either our Board of Directors, or a designated committee thereof composed of two or more Non-Employee Directors, to grant to eligible individuals up to 1,365,000 shares in the form of specified equity awards including stock options, restricted stock units (RSUs) and performance share units (PSUs), subject to adjustment for future stock splits, stock dividends, expirations, forfeitures, and similar events. In addition, the 2023 Plan includes any shares which were available for issuance under the 2007 Plan at the time of stockholder approval of this plan and shares which become available as a result of the forfeiture or expiration of awards made under the 2007 Plan.

As of October 31, 2023, 1,376,240 shares remained available under the 2023 Plan for future grants. The amount of available shares includes shares which may be distributed under performance shares.

Share-Based Compensation

The compensation expense and related income tax benefit recognized in our Consolidated Statements of Income for share-based awards, including the Employee Stock Purchase Plan, were as follows:


October 31,
(In millions)	2023		2022		2021
Selling, general and administrative expense	$	54.8	$	46.7	$	38.4
Cost of sales	4.2		4.5		3.9
Research and development expense	3.1		3.0		2.4
Total compensation expense	$	62.1	$	54.2	$	44.7
Related income tax benefit	$	5.0	$	5.0	$	5.6

Stock Options

The fair value of each stock option award granted is estimated on the date of grant using the Black-Scholes option valuation model and assumptions noted in the following table.


Years Ended October 31,	2023		2022		2021
Expected life	4.5 years		4.1 years		4.0 years
Expected volatility	29.5	%	25.8	%	30.3	%
Risk-free interest rate	3.8	%	1.1	%	0.3	%
Dividend yield	0.02	%	0.02	%	0.02	%

The activity and status of our stock option plans are summarized below:


	Number of Shares	Weighted- Average Exercise Price Per Share		Weighted- Average Remaining Contractual Term (in years)	Aggregate Intrinsic Value
Outstanding at October 31, 2022	1,063,843	$	264.85
Granted	86,241	$	329.83
Exercised	(71,808)	$	155.45
Forfeited or expired	(720)	$	337.72
Outstanding at October 31, 2023	1,077,556	$	277.29	5.36	$	53,510,367
Vested and expected to vest at October 31, 2023	1,059,841	$	276.11	5.32	$	53,475,275
Vested and exercisable at October 31, 2023	729,591	$	248.34	4.38	$	50,797,891

The weighted-average fair value of options granted during fiscal 2023, 2022 and 2021, estimated as of the grant date using the Black-Scholes option pricing model, was $103.17, $90.41 and $84.10, respectively. The total intrinsic value of options exercised during the fiscal years ended October 31, 2023, 2022 and 2021 was $13.4 million, $6.6 million and $64.7 million, respectively.

Stock options outstanding under our current plans have been granted at prices which are either equal to or above the market value of the common stock on the date of grant. Options granted under the 2007 Plan and 2023 Plan generally vest over a range of three to five years based on service conditions and expire no later than ten years after the grant date. We generally recognize compensation expense ratably over the vesting period. As of October 31, 2023, there was $17.6 million of total unrecognized compensation cost related to nonvested options, which is expected to be recognized over a remaining weighted-average vesting period of 2.1 years.

Restricted Stock Units

RSUs granted under the 2007 Plan and the 2023 Plan generally vest over three to five years. The grant-date fair value of RSUs is estimated based on the market price of our common stock. We recognize compensation expense ratably over the vesting period. As of October 31, 2023, there was $63.1 million of total unrecognized compensation cost related to nonvested RSUs, which is expected to be recognized over a remaining weighted-average vesting period of 2.4 years. The total fair value of RSU grants that vested during the fiscal years ended October 31, 2023, 2022 and 2021 was $37.3 million, $46.1 million and $50.1 million, respectively.

The status of our non-vested RSUs is summarized below:


	Number of Shares	Weighted- Average Grant Date Fair Value Per Share
Non-vested RSUs at October 31, 2022	289,238	$	340.68
Granted	145,655	$	335.32
Vested and issued	(107,403)	$	320.22
Forfeited or expired	(37,461)	$	344.72
Non-vested RSUs at October 31, 2023	290,029	$	345.03

Performance Units

Performance units may be granted to selected key employees with vesting contingent upon meeting certain performance goals over a defined performance cycle, usually three years. Performance units, if earned, may be paid in cash or shares of common stock. We granted performance unit awards on December 13, 2022, December 7, 2021, and December 8, 2020, under the 2007 Plan, with three-year performance periods ending in fiscal 2025, fiscal 2024, and fiscal 2023 respectively. The performance shares actually earned will range from zero to 200% of the target number of performance shares. Subject to limited exceptions set forth in the performance share agreement, any shares earned will be distributed in the subsequent fiscal year after the performance period. The fair value of performance unit awards is estimated on the date of grant based on the current market price of our common stock. The amount of compensation expense related to these performance unit awards is reviewed each fiscal quarter and adjustments are recorded after assessing the probability of achieving the performance goals.

We recognize compensation expense ratably over the vesting period. As of October 31, 2023, there was $12.3 million of total unrecognized compensation cost related to non-vested performance units, which is expected to be recognized over a remaining weighted-average vesting period of 1.7 years.

Employee Stock Purchase Plan

On March 18, 2019, the Company received stockholder approval for the Employee Stock Purchase Plan (ESPP). The first offering period began on November 4, 2019, and offerings are generally made on a quarterly basis. The purpose of the ESPP is to provide eligible employees of the Company with the opportunity to acquire shares of common stock at 85% of the market price on the last business day of each offering period by means of accumulated payroll deductions. The ESPP initially authorized the issuance of 1,000,000 shares of common stock. These shares will be made available from shares of common stock reacquired by the Company as Treasury Stock. During fiscal 2023 and 2022, we issued 26,116 and 22,695 shares to our employees under the ESPP, respectively. At October 31, 2023, the number of shares remaining available for future issuance under the ESPP was 921,975 shares. Total ESPP share-based compensation recognized during fiscal 2023 and 2022 was $1.3 million and $1.1 million, respectively.

Employee Benefits - Weighted-Average Assumptions Used in Computing Net Periodic Pension Cost and Projected Benefit Obligation (Details)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Discount rate for determining net periodic pension cost:
Projected Benefit Obligation	5.74%	2.76%	2.78%
Service Cost	5.77%	2.79%	2.86%
Interest Cost	5.51%	2.28%	2.07%
Discount rate for determining benefit obligations at year end	6.22%	5.74%	2.76%
Rate of compensation increase for determining expense	3.60%	3.60%	3.60%
Rate of compensation increase for determining benefit obligations at year end	3.60%	3.60%	3.60%
Expected rate of return on plan assets for determining net periodic pension cost	8.00%	8.00%	8.00%
Expected rate of return on plan assets at year end	8.00%	8.00%	8.00%

Employee Benefits - Components of Net Periodic Pension Costs and Other Amounts Recognized in Other Comprehensive Income (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Components of net periodic benefit cost and other amounts recognized in the Consolidated Statements of Income:
Service cost	$ 10.0	$ 18.3	$ 17.2
Interest cost	$ 7.9	$ 5.1	$ 4.4
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Expected Return (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Expected return on plan assets	$ (11.1)	$ (15.5)	$ (12.5)
Defined Benefit Plan, Net Periodic Benefit (Cost) Credit, Immediate Recognition of Actuarial Gain (Loss), Statement of Income or Comprehensive Income [Extensible Enumeration]	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)	Other Nonoperating Income (Expense)
Recognized actuarial loss	$ 0.0	$ 2.2	$ 5.4
Net periodic pension cost	$ 6.8	$ 10.1	$ 14.5

Financial Derivatives and Hedging

12 Months Ended

Oct. 31, 2023

Derivative Instruments and Hedging Activities Disclosure [Abstract]

Financial Derivatives and Hedging

Note 13. Financial Derivatives and Hedging

As part of the Company’s overall risk management practices the Company enters into financial derivatives, interest rate swaps designated as cash flow hedges, to hedge the Company's exposure to changes in cash flows associated with its variable rate debt.

Credit risk related to derivative transactions reflects the risk that a party to the transaction could fail to meet its obligation under the derivative contracts. Therefore, the Company’s exposure to the counterparty’s credit risk is generally limited to the amounts, if any, by which the counterparty’s obligations to the Company exceed the Company’s obligations to the counterparty. The Company’s policy is to enter into contracts only with financial institutions which meet certain minimum credit ratings to help mitigate counterparty credit risk. From time to time, the Company enters into foreign currency forward contracts to minimize the short-term impact of foreign currency exchange rate fluctuations on certain trade and intercompany receivables and payables. These foreign currency forward contracts are not designated as hedging instruments, and therefore the net change in their fair value is reported as a gain or loss in the Consolidated Statements of Income and Comprehensive Income. As of October 31, 2023, the notional amount of outstanding foreign currency forward contracts was $56.2 million. The resulting impact on our Consolidated Financial Statements from currency hedging activities was not significant for the years ended October 31, 2023, 2022 and 2021.

As of October 31, 2023, the Company has six interest rate swap contracts that have a total notional amount of $1.3 billion and remaining maturities of four years or less.

The following table summarizes the amounts recognized with respect to our derivative instruments within the accompanying Consolidated Statements of Income:


Periods Ended October 31,
(In millions)		2023		2022		2021
Derivatives designated as cash flow hedges	Location of (Gain)/Loss Recognized on Derivatives
Interest rate swap contracts	Interest expense (income)	$	(43.1)	$	(2.3)	$	8.0

The cumulative pre-tax impact of the gain on derivatives designated for hedge accounting is recognized in "Accumulated other comprehensive loss". The following table details the changes in the cumulative pre-tax impact of the gain on derivatives designated for hedge accounting:


(In millions)	Amount
Balance gain as of October 31, 2021	$	17.2
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($79.7, net of tax)	105.1
Amount reclassified from other comprehensive income into earnings, gross ($1.7, net of tax)	2.2
Balance gain as of October 31, 2022	$	124.5
Amount recognized in other comprehensive income on interest rate swap contracts, gross ($25.7, net of tax)	33.7
Amount reclassified from other comprehensive income into earnings, gross ($(32.7), net of tax)	(43.1)
Balance gain as of October 31, 2023	$	115.1

Refer to Note 8. Stockholders’ Equity for amounts presented net of the related tax impact in "Accumulated other comprehensive loss".

The Company expects that $(48.2) million recorded as a component of "Accumulated other comprehensive loss" will be realized in our Consolidated Statements of Income over the next twelve months and the amount will vary depending on prevailing interest rates.

Operating Leases - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Leases [Abstract]
Operating lease expense	$ 48.1	$ 45.0	$ 44.1

Income Taxes - Narrative (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
Income Taxes - Narrative (Details) - USD ($) $ in Millions	Jul. 31, 2021	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021	Jan. 31, 2021
Operating Loss Carryforwards [Line Items]
Deferred tax asset, intra-entity sale of certain intellectual property rights					$ 1,987.9
Remeasurement of deferred tax assets from UK rate change	$ (536.7)	$ 0.0	$ 0.0	$ (536.7)
Unrecognized tax benefits that would impact the effective tax rate		323.2	324.3	336.5
Accrued gross interest and penalties related to uncertain tax positions		5.8	$ 5.4	$ 6.4
Significant change in unrecognized tax benefits that is reasonably possible during the next twelve months		8.1
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards		78.7
Federal net operating losses expiring		46.0
Federal net operating losses not subject to expiration		32.7
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards		$ 87.1

Stock Plans - Assumptions Used in Estimating Fair Value of Stock Options Award Granted (Details)	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life			4 years
Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life	4 years 6 months	4 years 1 month 6 days
Expected volatility	29.50%	25.80%	30.30%
Risk-free interest rate	3.80%	1.10%	0.30%
Dividend yield	0.02%	0.02%	0.02%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

Consolidated Statements of Comprehensive Income - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Statement of Comprehensive Income [Abstract]
Net income	$ 294.2	$ 385.8	$ 2,944.7
Other comprehensive income (loss):
Cash flow hedges, net of tax of $(2.4), $26.1 and $8.2, respectively	(7.0)	81.3	26.1
Change in minimum pension liability, net of tax of $1.0, $8.7 and $7.2, respectively	3.0	27.9	22.6
Foreign currency translation adjustment	17.0	(234.7)	82.0
Other comprehensive income (loss)	13.0	(125.5)	130.7
Comprehensive income	$ 307.2	$ 260.3	$ 3,075.4

- Definition

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount after tax and reclassification adjustments of other comprehensive income (loss).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-SubTopic 10
-Topic 505
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481674/830-30-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-17

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-4

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-5

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 830
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481694/830-30-45-20

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 15
-SubTopic 10
-Topic 220
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482739/220-10-55-15

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

+ Details

Employee Benefits - Narrative (Details) - USD ($) $ in Millions	12 Months Ended
	Oct. 31, 2023	Oct. 31, 2022	Oct. 31, 2021
Defined Benefit Plan Disclosure [Line Items]
Accumulated benefit obligation	$ 131.5	$ 134.9	$ 207.6
Discount rate	5.74%	2.76%	2.78%
Defined benefit obligation, actuarial gain (loss)	$ 10.9	$ 93.2	$ (2.0)
Expected long-term return on diversified portfolio	8.00%
Employer contributions	$ 1.1	0.0	12.7
Expected future employer contributions	$ 1.1
Maximum annual contributions per employee in 401k savings plan	75.00%
Contributions by employer in 401k savings plan	$ 10.1	$ 9.0	$ 7.2
Minimum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Diversified portfolio, allocation of assets in equities	50.00%
Maximum \| Equity Securities
Defined Benefit Plan Disclosure [Line Items]
Diversified portfolio, allocation of assets in equities	70.00%
Change In Assumptions For Defined Benefit Plans, Change In Key Assumptions
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	$ 12.9
Change In Assumptions For Defined Benefit Plans, Change In Demographic Experience
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	(2.0)
Change In Assumptions For Defined Benefit Plans, Change In Discount Rate
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	7.8
Change In Assumptions For Defined Benefit Plans, Change In Lump Sum Determination
Defined Benefit Plan Disclosure [Line Items]
Defined benefit obligation, actuarial gain (loss)	$ 5.1